

CURRICULUM VITAE



Prof. Dr. med. Christian Ulrich Blank
MD PhD MBA

Curriculum vitae

Personal data

Name: Prof. Dr. Christian Ulrich Blank
Date of birth: 03.08.1972
Place of birth: Berlin-West
Nationality: German
Present position: Staff member Medical Oncology and
Staff Scientist Division of Immunology
Titles: Internist
Medical Oncologist/Haematologist
MBA (DLMBA, Warwick, UK)
Professor (University of Regensburg, Germany)
Professor (Leiden University Medical Center, LUMC, Netherlands)
Institution: The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
Departments: Department of Medical Oncology, Division of Immunology
Plesmanlaan 121, 1066CX Amsterdam, The Netherlands
phone: +31-20-512-2960; fax: +31-20-512-2572
email: c.blank@nki.nl

Education

1978-1982 Elementary school
1982-1991 Grammar school (Gymnasium)
1991-1992 Military service
1992-1994 Medical school University of Regensburg, Germany, Internship Casualty
Department St. Luke's Hospital, Valletta, Malta
1994-1997 Medical school University of Munich (TUM), Germany
1997-1998 Praktisches Jahr (Junior house officer) at Department of Cardiology, the
Department of Radiology, both at the University Clinic Munich Rechts der
Isar, Germany, at the A&E Department Royal Infirmary of Edinburgh, UK,
and the A&E University of Birmingham
1998-2000 Arzt im Pratikum (AiP, internship years) at Department Haematology/
Oncology, University Clinic Regensburg
1999 A&E specialization
2001-2003 Post-Doc, University of Chicago, USA, grant by the National Academy of
Science Leopoldina
2001-2006 Master of Business Administration (MBA), distance learning at the University
of Warwick, UK
2003-2007 Specialist training internal medicine and haematology/oncology at University
Clinic Regensburg
2007 Facharzt/Board registration internal medicine
2009 Facharzt/Board registration haematology/oncology
2010 GCP registration (re-registration 12/2012, 7/2014 and 11/2015, BROK
10/2018)

Clinical Work

1998-2001	Physician at the Department of Haematology and Oncology, University of Regensburg (rotations to GE, rheumatology, endocrinology, hepatology)
2003-2007	Physician at the Department of Haematology and Oncology, University of Regensburg (rotations also to cardiology, pulmonology, nephrology, intensive care, A&E, ultrasound, bone marrow diagnostics, transfusion medicine, H/O outpatient clinic)
2006-2008	Emergency physician at the University Clinic of Regensburg
since 2007	Physician at the Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital (NKI-AVL)
since 2010	Privatdozent (university lecturer) at the University of Regensburg
since 2015	Professor at the Haematology/Medical Oncology Department, University of Regensburg
since 2020	Professor for Cancer Immunotherapy at the Medical Department, Leiden University Medical Center (LUMC)
since 2025	Head of the Division Melanoma and Sarcoma at the European Institute Oncology (IEO), Milano

Basic Research

1994-1997	Doctoral thesis at the Department for Medical Microbiology, Immunology and Hygiene, Technical University Munich, Germany, headed by Prof. Hermann Wagner, awarded summa cum laude
2001-2003	Research Fellowship (post-doc) at the Department of Medicine, Section Haematology/Oncology, University of Chicago, USA, lab of Prof. Thomas Gajewski
2003 - 2007	Research group leader at the University of Regensburg, Department Haematology/Oncology,
since 2007	Group leader, NKI-AVL, Department of Immunology, Amsterdam

Additional skills

Courses:	Sports medicine (1999-2004, TU Munich) Clinical statistics (2002, University of Chicago) Naturopathic treatment (1999-2000, TU Munich) Haematology diagnostics (2000, Lippstadt) A&E specialization (1999, Garmisch Patenkirchen) Medical English, (1999 TU Munich and TU Dresden)
Languages:	German (native language) English (fluent) Dutch (fluent) Italian (B2) French (basics)
Hobbies:	Snowboarding, racing bicycle, reading, travelling, cooking, open water swimming

Memberships

German Society of Biochemistry and Molecular Biology (1993-2006)
German Society of Internal Medicine (1999-2013)
German Society of Immunology (2000-2007)
German Society of Haematology/Oncology (2004-2013)
Dutch Society of Internal Medicine (since 2008)
Dutch Society of Oncology (since 2010)
European Society for Medical Oncology, ESMO (since 2010)
American Society of Oncology, ASCO (since 2010)

Honours and awards

1999 Doctor of medicine, summa cum laude
2000 Promotionspreis Faculty of medicine TUM
2003 Travel Award UCCRC Immunology Program
2004 Helga-Reifert-Award for experimental cancer research
2005 Keystone Symposia Scholarship Award
2011 Habilitation and award of Privatdozent (university lecturer) at the University of Regensburg
2015 Professor at the University of Regensburg, Department Hematology and Medical Oncology
2020 Professor for Cancer Immunotherapy at the Medical Department, Leiden University Medical Center (LUMC)

Teaching & lecturing

2007-present Lecturer, physician courses, NKI-AVL, Amsterdam
2011-present Lecturer, haematology/oncology courses, Medical School, University of Regensburg
2013-present Lecturer, tumour immunology course, Free university (VU), Amsterdam
2015-present Lecturer, ESMO Academy Oxford, and ESMO Preceptorship Courses

Clinical Trials Experience

Principal investigator (PI) MARIANE trial (NCT06240143), international multi-centre investigator-initiated phase 1b study
PI NADINA trial (NCT04949113), international multi-centre investigator-initiated phase III study
PI DONIMI trial (NCT04133948), international multi-centre investigator-initiated phase Ib study
PI OpACIN-neo and PRADO extension trial (NCT02977052), international multi-centre investigator-initiated phase II study
PI IMPemBra (NCT02625337), investigator-initiated phase II study
Co-PI, COWBOY trial (NCT02968303), investigator-initiated multi-centre phase III trial
Co-PI, TONIC trial (NCT02499367), investigator-initiated phase II trial
PI, M16CNI, phase III pharma study
PI, OpACIN trial (NCT02437279), investigator-initiated phase Ib study
Sub-investigator (Sub-I), REPOSIT trial (NCT02414750), investigator initiated phase II study
PI, M14GO, phase Ib/II pharma study
Sub-I M14TIL (NCT02278887), phase III investigator initiated study

PI M14LOG, phase II pharma study
 PI M13MKI, phase III pharma study
 PI M13MME, phase III pharma study
 PI M13MKM, phase II pharma study
 Sub-I M13NIM, phase III pharma study
 Sub-I M13DTA, phase III pharma study
 Sub-I M12BIC, phase III pharma study
 PI SECIRA-UM (NTR3488), phase Ib/II investigator-initiated study
 PI M11BRI, phase IV pharma study
 PI M11MME, phase II pharma study
 PI M10BRA, phase III pharma study
 Sub-I M09BRIM, phase III pharma study
 PI M09RCC, phase IV pharma study
 Sub-IM09PSR, phase III pharma study
 Sub-IM07ILS, phase II pharma study
 Sub-I MDX010, NKI-AVL, phase III pharma study
 Sub-I MDX010, University of Regensburg, phase III pharma study

Awarded grants & funded investigator-initiated trials

2001-2003	National Academy of Sciences Leopoldina: Post-doc grant (60.000 €)
2003-2004	ReForm-A (Regensburg start-up funding): Negative co-stimulation of T cell activation via PD-1/PD-L1/L2 interaction (40.000 €)
2004-2007	German Cancer Foundation (DKH): The role of PD-L1 for the negative regulation of tumour specific human CD8+ T cells (100.000 €)
2004-2007	German Research Society (DFG): Molecular characterization of homeostatic proliferating CD8+ T cells (100.000 €)
2005-2007	Wilhelm Sander Foundation: Immunomodulatory function of PD-L1. Blockade of PD-1 as possible clinical treatment option (85.000 €)
2007-2012	Dutch Cancer Society: Blockade of PD-1/PD-L1 interaction to improve T cell mediated immunotherapy of cancer (725.000 €)
2010-2011	Start-up funding NKI-AVL: Preclinical testing of TIL from RCC patients (100.000 €)
2011-2013	MedImmune grant: Evaluation of combined T cell checkpoint blockade in an induced melanoma model (310.000 €)
2012-2017	Bristol-Myers Squibb: Phase Ib/II study exploring safety and efficacy of the combination of ipilimumab with radiofrequency ablation (RFA) in patients with unresectable uveal melanoma liver metastasis (SECIRA-UM), CA184-180/N11RFA (470.00 €)
2011-2013	Melanoma Research alliance: Development of immuno- and molecular combination therapy for human melanoma (225.000 \$)
2013-2015	Novartis Research Grant: Triple and quadruple targeted therapy in a mouse model of human BRAFV600mut melanoma (60.000 €)

2014-2018	International Immune Oncology Network (II-ON) Bristol-Myers Squibb: Feasibility Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN) in resectable stage III melanoma patients, CA209-278/N14OPC (680.000 €)
2015-2018	Merck (MSD): Phase 2 Study Comparing Pembrolizumab with Intermittent/Short-term Dual MAPK Pathway Inhibition Plus Pembrolizumab in patients harboring the BRAFV600 mutation (IMPemBra), N15IMP (850.000 €)
2016-2020	Bristol-Myers Squibb: Multicenter Phase 2 Study to Identify the Optimal neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo), CA209-701/M16OPN (1.380.000 € excl. TR budget)
2017	II-ON: TCR sequencing analyses within the OpACIN trial (60.000 €)
2017-2018	II-ON: Improve the understanding of systemic melanoma-mediated immune suppression by deep serum profiling (660.000 €)
2017-2018	II-ON: Systematic analysis of Cutaneous and Uveal Melanoma (405.000 €)
2018-2021	Bristol-Myers Squibb: Expansion cohort OpACIN-neo: Personalized Response-driven neo-adjuvant combination of Ipilimumab and Nivolumab in macroscopic stage IIIB/C melanoma - PRADO (1.176.000 € excl. TR budget)
2019-2023	Melanoma Research Alliance (MRA) team science award: Overcoming upfront resistance to neoadjuvant combined CTLA-4 plus PD-1 blockade (754.680 €)
2020-2022	II-ON: Characterization of stage III melanoma non-responders upon neoadjuvant IPI1 NIVO3 by TMB, RNA-signature analyses and single cell surface markers (552.800 €)
2020-2023	4SC: Multicenter Phase 1b Trial testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma signature-low and IFN-gamma signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma – DONIMI (2,108,699 €)
2021-2023	Building a historic patient cohort of patients treated with dabrafenib + trametinib as control group for future patient management based on reported adverse events and QoL reporting during targeted therapy (71,599€)
2021-2028	Bristol Meyers Squibb International – ‘Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma – NADINA’ (10,527,708€)
2025-2028	Dutch Cancer Foundation (KWF) - Novel immune inhibitory mechanisms in melanoma predict efficacy to (neo)-adjuvant immunotherapy (839,482€, shared with Prof Yvette van Kooyk, Amsterdam UMC)

Publications

1. **Blank C**, Luz A, Bendigs S, Erdmann A, Wagner H, Heeg K. Superantigen and endotoxin synergize in the induction of lethal shock. *Eur J Immunol.* 1997 Apr;27(4):825-33.
2. Lipford GB, Bauer M, **Blank C**, Reiter R, Wagner H, Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. *Eur J Immunol.* 1997 Sep;27(9):2340-4.
3. **Blank C**, Wagner HM, Hohenleutner U, Andreesen R. Rash and Leukaemia - NEH: paraneoplastic or drug-induced? *J Clin Oncol.* 2000 Oct 1;18(19):3437-9.
4. Hwang KW, Sweatt WB, Brown IE, **Blank C**, Gajewski TF, Bluestone JA, Alegre ML. Targeted Ligation of CTLA-4 In Vivo by Membrane-Bound Anti-CTLA-4 Antibody Prevents Rejection of Allogeneic Cells. *J Immunol.* 2002 Jul 15;169(2):633-7.
5. **Blank C**, Brown I, Marks R, Nishimura H, Honjo T, Gajewski TF. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. *J Immunol.* 2003 Nov 1;171(9):4574-81.
6. **Blank C**, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8⁺ T Cells. *Cancer Res.* 2004 Feb 1;64(3):1140-5.
7. Zha Yy, **Blank C**, Gajewski TF. Negative regulation of T cell function by PD-1. *Crit Rev Immunol.* 2004;24(4):229-37.
8. **Blank C**, Gajewski TF, Mackensen A. Interaction of PD-L1 on Tumor cells with PD-1 on Tumor-specific T cells as a Mechanism of Immune Evasion – Implications for Tumor Immunotherapy. *Cancer Immunol Immunother.* 2005 Apr;54(4):307-14.
9. **Blank C**, Brown I, Kacha AK, Markiewicz MA, Gajewski TF. ICAM-1 contributes to but is not absolutely required for CD8⁺ T cell-mediated tumor rejection in vivo. *J Immunol.* 2005 Mar 15;174(6):3416-20.
10. **Blank C**, Mackensen, A. Wie Tumorzellen dem Immunsystem entkommen – PD-1/PD-L1 Interaktion als neuer Mechanismus bei der Tumorresistenz. *Journal Onkologie* 2006 Jan 18; (5): 36-38
11. **Blank C**, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. *Int J Cancer.* 2006 Jul 15;119(2):317-27.
12. Brown IE, **Blank C**, Kline J, Kacha AK, Gajewski TF. Homeostatic Proliferation as in isolated variable reverses CD8⁺ T cell anergy and promotes tumor rejection in vivo. *J*

Immunol. 2006 Oct 1;177(7):4521-9.

13. Mühlbauer M, Fleck M, Schütz C, Weiss T, Froh M, **Blank C**, Schölmerich J, Hellerbrand C. PD-L1 is induced in hepatocytes by viral infection and by interferon- α and - γ and mediates T cell apoptosis. *J Hepatol.* 2006 Oct;45(4):520-8.
14. Gajewski TF, Meng Y, **Blank C**, Brown I, Kacha A, Kline J, Harlin H. Immune resistance orchestrated by the tumor environment. *Immunol Rev.* 2006 Oct;213:131-45.
15. **Blank C**, Mackensen A. Contribution of the PD-L1/PD-1 Pathway to T-Cell Exhaustion: Implications for Chronic Infections and Tumor Evasion. *Cancer Immunol Immunother.* 2007 May;56(5):739-45
16. Hart C, **Blank C**, Krause SW, Andreesen R, and Hennermann B. Ifosfamide, epirubicin, and etoposide (IEV) mobilize peripheral blood stem cells more efficiently than cyclophosphamide/etoposide. *Ann Hematol.* 2007 Aug;86(8):575-81
17. Brem-Exner BG, Sattler C, Hutchinson JA, Koehl GE, Kronenberg K, Farkas S, Inoue S, **Blank C**, Knechtle SJ, Schlitt HJ, Fändrich F, Geissler EK. Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. *J Immunol.* 2008 Jan 1;180(1):335-49.
18. Kline J, Brown IE, Zha YY, **Blank C**, Strickler J, Wouters H, Zhang L, Gajewski TF. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. *Clin Cancer Res.* 2008 May 15;14(10):3156-67.
19. Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, Castermans E, Thor Straten P, **Blank C**, Haanen JB, Heemskerk MH, Schumacher TN. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. *Nat Methods.* 2009 Jul;6(7):520-6.
20. Bex A, van der Veldt AA, **Blank C**, van den Eertwegh AJ, Boven E, Horenblas S, Haanen J. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. *World J Urol.* 2009 Aug;27(4):533-9.
21. Schuster K, Gadiot J, Andreesen R, Mackensen A, Gajewski TF, **Blank C**. Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN. *Eur J Immunol.* 2009 Nov;39(11):2981-90.
22. Strizzi L, Postovit LM, Margaryan NV, Lipavsky A, Gadiot J, **Blank C**, Seftor RE, Seftor EA, Hendrix MJ. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. *Expert Rev Dermatol.* 2009;4(1):67-78.

23. Bex A, Van der Veldt AA, **Blank C**, Meijerink MR, Boven E, Haanen JB. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. *Acta Oncol.* 2010 May;49(4):520-3.
24. Borkner L, Kaiser A, van de Kastele W, Andreesen R, Mackensen A, Haanen JB, Schumacher TN, **Blank C**. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. *Cancer Immunol Immunother.* 2010 Aug;59(8):1173-83.
25. Powles T, Kayani I, **Blank C**, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boletti K, Sadev A, O'Brien T, Berney D, Beltran L, Haanen J, Bex A. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. *Ann Oncol.* 2011 May;22(5):1041-7.
26. Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, **Blank C**. Overall survival and PD-L1 expression in metastasized malignant Melanoma. *Cancer.* 2011 May 15;117(10):2192-201.
27. Bex A, Larkin J, **Blank C**. Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities. *Curr Oncol Rep.* 2011 Jun;13(3):240-8.
28. Powles T, **Blank C**, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boletti E, Sahdev A, O'Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. *Eur Urol.* 2011 Sep;60(3):448-54.
29. Bex A, **Blank C**, Meinhardt W, van Tinteren H, Horenblas S, Haanen J. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. *Urology.* 2011 Oct;78(4):832-7.
30. **Blank CU**, Hooijkaas AI, Haanen JBAG, and Schumacher TNM. Combination of targeted therapy and immunotherapy in melanoma. *Cancer Immunol Immunother.* 2011 Oct;60(10):1359-71.
31. Lankheet NA, **Blank CU**, Mallo H, Adriaansz S, Rosing H, Schellens JH, Huitema AD, Beijnen JH. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. *J Anal Toxicol.* 2011 Oct;35(8):558-65.
32. Hooijkaas AI, Gadiot J, van Boven H, **Blank C**. Expression of the embryological morphogen Nodal in stage III/IV melanoma. *Melanoma Res.* 2011 Dec;21(6):491-501.

33. Vogel WV, Guislain A, Kvistborg P, Schumacher TN, Haanen JB, **Blank CU**. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. *J Clin Oncol*. 2012 Jan 10;30(2):e7-e10.
34. Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, **Blank CU**, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirota N, Bodrogi I; on behalf of the REACT Study Group. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. *Eur J Cancer* 2012, Feb;48(3):324-32.
35. Kaiser AD, Schuster K, Gadiot J, Borkner L, Daebritz H, Schmitt C, Andreesen R, **Blank C**. Reduced tumor-antigen density leads to PD-1/PD-L1 mediated impairment of partially exhausted CD8(+) T cells. *Eur J Immunol*. 2012 Mar;42(3):662-71.
36. Krönig H, Julia Falchner K, Odendahl M, Brackertz B, Conrad H, Muck D, Hein R, **Blank C**, Peschel C, Haller B, Schulz S, Bernhard H. PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease. *Int J Cancer*. 2012 May 15;130(10):2327-36.
37. Bex A, Etto T, Vyth-Dreese F, **Blank C**, Griffioen AW. Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response? *Curr Oncol Rep*. 2012 Jun;14(3):230-9.
38. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, **Blank CU**, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*. 2012 Jul 28;380(9839):358-65.
39. Mougiakakos D, Okita R, Ando T, Dürr C, Gadiot J, Ichikawa J, Zeiser R, **Blank C**, Johansson C, Kiessling R. High Expression of GCLC is Associated with Malignant Melanoma of Low Oxidative Phenotype and Predicts a Better Prognosis. *Journal of Molecular Medicine*. 2012 Aug;90(8):935-44.
40. Bot I, **Blank CU**, Brandsma D. Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. *J Neurol*. 2012, Sep;259(9):1976-8.
41. Hooijkaas A, Gadiot J, Morrow M, Stewart R, Schumacher T, **Blank CU**. Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. *Oncoimmunology*. 2012 Aug 1;1(5):609-617.

42. Hooijkaas AI, Gadiot J, van der Valk M, Mooi WJ, **Blank CU**. Targeting BRAF(V600E) in an Inducible Murine Model of Melanoma. *Am J Pathol*. 2012 Sep;181(3):785-94.
43. Kaiser AD, Gadiot J, Guislain A, **Blank CU**. Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts. *Cancer Immunol Immunother*. 2013 Mar 62(3):503-15.
44. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, **Blank CU**, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised open-label phase 2 study. *Lancet Oncol* 2013 Mar;14(3):249-56.
45. Van der Hiel B, **Blank CU**, Haanen JB, Stokkel MP. Detection of Early Onset of Hypophysitis by 18F-FDG PET-CT in a Patient with Advanced Stage Melanoma Treated with Ipilimumab. *Clin Nucl Med*. 2013 Apr;38(4): e182-4.
46. Bot I, **Blank CU**, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. *Pract Neurol*. 2013 Aug;13(4):278-80.
47. Powles T, Kayani I, Sharpe K, Lim L, Peters J, Stewart GD, Berney D, Sahdev A, Chowdhury S, Boleti E, Shamash J, Reynolds AR, Jones R, **Blank C**, Haanen J, Bex A. A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. *Ann Oncol*. 2013 Aug;24(8):2098-103.
48. Kelderman S, van der Kooij MK, van den Eertwegh AJ, Soetekouw PM, Jansen RL, van den Brom RR, Hospers GA, Haanen JB, Kapiteijn E, **Blank CU**. Ipilimumab in pretreated metastatic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). *Acta Oncol*. 2013 Nov;52(8):1786-8.
49. Lankheet NA, Huitema AD, Mallo H, Adriaansz S, Haanen JB, Schellens JH, Beijnen JH, **Blank CU**. The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome. *Eur J Clin Pharmacol*. 2013 Dec;69(12):2065-72.
50. Linnemann C, Heemskerk B, Kvistborg P, Kluin RJ, Bolotin DA, Chen X, Bresser K, Nieuwland M, Schotte R, Michels S, Gomez-Eerland R, Jahn L, Hombrink P, Legrand N, Shu CJ, Mamedov IZ, Velds A, **Blank CU**, Haanen JB, Turchaninova MA, Kerkhoven RM, Spits H, Hadrup SR, Heemskerk MH, Blankenstein T, Chudakov DM, Bendle GM, Schumacher TN. High-throughput identification of antigen-specific TCRs by TCR gene capture. *Nat Med*. 2013 Nov;19(11):1534-41.]
51. Gadiot J, Hooijkaas AI, Deken MA, **Blank CU**. Synchronous BRAFV600E and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity. *Onco Targets Ther*. 2013 Nov 28;6:1649-58.

52. Krönig H, Kremmler L, Haller B, Englert C, Peschel C, Andreesen R, **Blank CU**. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human AML blast cells during treatment. *Eur J Haematol*. 2014 Mar;92(3):195-203.
53. **Blank C**. The perspective of immunotherapy - new molecules and new mechanisms of action in immune modulation. *Curr Opin Oncol*. 2014 Mar;26(2):204-14.
54. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, **Blank CU**. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. *Lancet Oncol*. 2014 Apr;15(4):436-44.
55. Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL, Fiets E, Furness AJ, Renn A, Krzystanek M, Szallasi Z, Lorigan P, Gore ME, Schumacher TN, Haanen JB, Larkin JM, **Blank CU**. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. *Cancer Immunol Immunother*. 2014 May;63(5):449-58.
56. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, **Blank C**, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Liefstink C, Mateus C, Vagner S, Grenrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. *Nature*. 2014 Apr 3;508(7494):118-22.
57. Rutkowski P, **Blank C**. Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation. *Expert Opin Drug Saf*. 2014 Sep;13(9):1249-58.
58. Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, Welters MJ, van der Burg S, Kapiteijn E, Michielin O, Romano E, Linnemann C, Speiser D, **Blank C**, Haanen JB, Schumacher TN. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. *Sci Transl Med*. 2014 Sep 17;6(254):254ra128.
59. Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Foppen MH, Kemper K, Goding CR, McDermott U, **Blank C**, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS. MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. *Nat Commun*. 2014 Dec 15;5:5712.
60. **Blank CU**, Enk A. Therapeutic use of anti-CTLA-4 antibodies. *Int Immunol*. 2015 Jan;27(1):3-10.
61. Scholtens A, Geukes Foppen MH, **Blank CU**, van Thienen JV, van Tinteren H, Haanen JB. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression. *Eur J Cancer*. 2015 Mar;51(5):642-52.

62. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, **Blank CU**, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; Pembrolizumab versus Ipilimumab in Advanced Melanoma. *N Engl J Med*. 2015 Jun 25;372(26):2521-32.
63. Haanen JB, Thienen Hv, **Blank CU**. Toxicity patterns with immunomodulating antibodies and their combinations. *Semin Oncol*. 2015 Jun;42(3):423-8.
64. van den Berg JH, Gomez-Eerland R, van de Wiel B, Hulshoff L, van den Broek D, Bins A, Tan HL, Harper JV, Hassan NJ, Jakobsen BK, Jorritsma A, **Blank CU**, Schumacher TN, Haanen JB. Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. *Mol Ther*. 2015 Sep;23(9):1541-50.
65. Kemper K, Krijgsman O, Cornelissen-Steijger P, Shahrabi A, Weeber F, Song JY, Kuilman T, Vis DJ, Wessels LF, Voest EE, Schumacher TN, **Blank CU**, Adams DJ, Haanen JB, Peeper DS. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. *EMBO Mol Med*. 2015 Sep;7(9):1104-18.
66. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, **Blank CU**, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. *Lancet Oncol*. 2015 Aug;16(8):908-18.
67. Guislain A, Gadiot J, Kaiser A, Jordanova ES, Broeks A, Sanders J, van Boven H, de Gruijl TD, Haanen JB, Bex A, **Blank CU**. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. *Cancer Immunol Immunother*. 2015 Oct;64(10):1241-50.
68. Van Allen EM, Miao D, Schilling B, Shukla SA, **Blank C**, Zimmer L, Sucker A, Hillen U, Foppen MH, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. *Science*. 2015 Oct 9;350(6257):207-11.
69. Schreiber G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Tel J, Winkels G, Petry K, Blokk WA, van Rossum MM, Welzen ME, Mus RD, Croockewit SA, Koornstra RH, Jacobs JF, Kelderman S, **Blank CU**, Gerritsen WR, Punt CJ, Figdor CG, de Vries IJ. Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. *Clin Cancer Res*. 2016 May 1;22(9):2155-66.

70. **Blank CU**, Haanen JB, Ribas A, Schumacher TN. The "cancer immunogram". *Science*. 2016 May 6;352(6286):658-60.
71. Martens A, Wistuba-Hamprecht K, Foppen MG, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, **Blank C**, Pawelec G, Garbe C, Weide B. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. *Clin Cancer Res*. 2016 Jun 15;22(12):2908-18.
72. Geukes Foppen MH, Brandsma D, **Blank CU**, van Thienen JV, Haanen JB, Boogerd W. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. *Ann Oncol*. 2016 Jun;27(6):1138-42.
73. Kemper K, Krijgsman O, Kong X, Cornelissen-Steijger P, Shahrabi A, Weeber F, van der Velden DL, Bleijerveld OB, Kuilman T, Kluin RJ, Sun C, Voest EE, Ju YS, Schumacher TN, Altelaar AF, McDermott U, Adams DJ, **Blank CU**, Haanen JB, Peeper DS. RAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. *Cell Rep*. 2016 Jun 28;16(1):263-77.
74. Kroon P, Gadiot J, Peeters M, Gasparini A, Deken MA, Yagita H, Verheij M, Borst J, **Blank CU**, Verbrugge I. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. *Cancer Immunol Immunother*. 2016 Jun;65(6):753-63.
75. Noe A, de Bruijn RE, **Blank C**, Horenblas S, Haanen J, Bex A. Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. *World J Urol*. 2016 Aug;34(8):1067-72.
76. Hoeller C, Michielin O, Ascierto PA, Szabo Z, **Blank CU**. Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma. *Cancer Immunol Immunother*. 2016 Sep;65(9):1015-34.
77. Wistuba-Hamprecht K, Martens A, Haehnel K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Demuth I, Steinhagen-Thiessen E, Larbi A, Schilling B, Schadendorf D, Wolchok JD, **Blank CU**, Pawelec G, Garbe C, Weide B. Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. *Eur J Cancer*. 2016 Sep;64:116-26.
78. Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, Pineda C, Geukes Foppen MH, Scolyer R, Song JY, Verbrugge I, Hoeller C, Dummer R, Haanen JB, Long GV, **Blank CU**. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. *Oncoimmunology*. 2016 Oct 14;5(12):e1238557.

79. Nijenhuis CM, Huitema AD, Marchetti S, **Blank C**, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. *J Clin Pharmacol.* 2016 Oct;56(10):1307-12.
80. Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O'Day S, Puzanov I, Schachter J, **Blank C**, Salama A, Loquai C, Mehnert JM, Hille D, Ebbinghaus S, Kang SP, Zhou W, Ribas A. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. *Eur J Cancer.* 2016 Nov;67:46-54.
81. Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, Kastenberger M, Bogdan C, Schleicher U, Mackensen A, Ullrich E, Fichtner-Feigl S, Kesselring R, Mack M, Ritter U, Schmid M, **Blank C**, Dettmer K, Oefner PJ, Hoffmann P, Walenta S, Geissler EK, Pouyssegur J, Villunger A, Steven A, Seliger B, Schreml S, Haferkamp S, Kohl E, Karrer S, Berneburg M, Herr W, Mueller-Klieser W, Renner K, Kreutz M. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. *Cell Metab.* 2016 Nov 8;24(5):657-671.
82. Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler KC, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, **Blank CU**, Schadendorf D, Dummer R, Ascierto PA, Hospers GA, Garbe C, Wolchok JD. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. *Clin Cancer Res.* 2016 Nov 15;22(22):5487-5496.
83. Cairns L, Aspeslagh S, Anichini A, Kyte JA, **Blank C**, Ascierto P, Rekers N, Straten PT, Awada A. Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation. *Ecancermedicalscience.* 2016 Nov 10;10:691.
84. **Blank C**. Biomarkers for outcome upon MAPK inhibition in melanoma. *Lancet Oncol.* 2016 Dec;17(12):1634-1636.
85. McArthur GA, Maio M, Arance A, Nathan P, **Blank C**, Avril MF, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Makrutzki M, Robson S, Gonzalez R, Margolin K. Vemurafenib in Metastatic Melanoma Patients with Brain Metastases: An Open-Label, Single-Arm, Phase 2, Multicentre Study. *Ann Oncol.* 2016 Dec 19.
86. Deken MA, Song JY, Gadiot J, Bins AD, Kroon P, Verbrugge I, **Blank CU**. Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice. *Int J Mol Sci.* 2016 Dec 20;17(12).
87. Van der Kooij MK, Joosse A, Speetjens FM, Hospers GA, Bisschop C, de Groot JW, Koornstra R, **Blank CU**, Kapiteijn E. Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands. *Acta Oncol.* 2017 Jan;56(1):101-103.

88. Nijenhuis CM, Huitema AD, **Blank C**, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients. *J Clin Pharmacol.* 2017 Jan;57(1):125-128.
89. Wistuba-Hamprecht K, Martens A, Heubach F, Romano E, Geukes Foppen M, Yuan J, Postow M, Wong P, Mallardo D, Schilling B, Di Giacomo AM, Khammari A, Dreno B, Maio M, Schadendorf D, Ascierto PA, Wolchok JD, **Blank CU**, Garbe C, Pawelec G, Weide B. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. *Eur J Cancer.* 2017 Mar;73:61-70.
90. Kandolf Sekulovic L, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, Dummer R, Forsea AM, Hoeller C, Gogas H, Demidov L, Lebbe C, **Blank C**, Olah J, Bastholt L, Hecceg D, Neyns B, Vieira R, Hansson J, Rutkowski P, Krajsova I, Bylaite-Bucinskiene M, Zalaudek I, Maric-Brozic J, Babovic N, Banjin M, Putnik K, Weinlich G, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Kukushkina M, De La Cruz Merino L, Ymeri A, Risteski M, Garbe C. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. *Eur J Cancer.* 2017 Mar 2;75:313-322.
91. Meerveld-Eggink A, Rozeman EA, Lalezari F, van Thienen JV, Haanen JB, **Blank CU**. Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients - a single center experience. *Ann Oncol.* 2017 Apr 1;28(4):862-867
92. **Blank CU**, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. *Eur J Cancer.* 2017 Jul;79:176-184
93. de Bruijn RE, Kuusk T, Noe AP, **Blank CU**, Haanen JBAG, Hendricksen K, Horenblas S, Bex A. Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma. *Urology.* 2017 Aug 2. pii: S0090-4295(17)30781-1. doi: 10.1016/j.urology.2017.06.048. [Epub ahead of print]
94. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, **Blank C**, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet.* 2017 Aug 16. pii: S0140-6736(17)31601-X.
95. Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland I, Broeks A, Horlings HM, Wessels LFA, **Blank CU**, Xiao Y,

- Heck AJR, Borst J, Brummelkamp TR, Schumacher TNM. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. *Nature*. 2017 Sep 7;549(7670):106-110
96. Kong X, Kuilman T, Shahrabi A, Boshuizen J, Kemper K, Song JY, Niessen HWM, Rozeman EA, Geukes Foppen MH, **Blank CU**, Peeper DS. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. *Nature*. 2017 Oct 12;550(7675):270-274.
97. Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, van Leerdam ME, van den Heuvel M, **Blank CU**, van Dieren J, Haanen JBAG. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. *ESMO Open*. 2018 Jan 13;3(1):e000278
98. Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, Vredevogd DW, Kemper K, Kuilman T, Song JY, Pencheva N, Mortensen JT, Foppen MG, Rozeman EA, **Blank CU**, Janmaat ML, Satijn D, Breij ECW, Peeper DS, Parren PWHI. Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. *Nat Med*. 2018 Feb;24(2):203-212
99. Geukes Foppen MH, Boogerd W, **Blank CU**, van Thienen JV, Haanen JB, Brandsma D. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma. *Melanoma Res*. 2018 Apr;28(2):126-133
100. Eggermont AMM, **Blank CU**, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khatkhat A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suci S, Robert C. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. *N Engl J Med*. 2018 May 10; 378(19): 1789-1801
101. Rozeman EA, Dekker TJA, Haanen JBAG, **Blank CU**. Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. *Am J Clin Dermatol*. 2018 Jun; 19(3) 303-317
102. Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, **Blank C**, Van De Wiel B, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, Mitchell T, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. *Ann Oncol*. 2018 Aug 1; 29(8): 1861-1868
103. Lacroix R, Rozeman EA, Kreutz M, Renner K, **Blank CU**. Targeting tumor-associated acidity in cancer immunotherapy. *Cancer Immunol Immunother*. 2018 Sep;67(9):1331-1348
104. Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, **Blank C**, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with

pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. *Eur J Cancer.* 2018 Sep;101:236-243

105. van Dijk N, Funt SA, **Blank CU**, Powles T, Rosenberg JE, van der Heijden MS. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. *Eur Urol.* 2018 Sep 28. pii: S0302-2838(18)30685-7. doi: 10.1016/j.eururo.2018.09.022. [Epub ahead of print]
106. **Blank CU**, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M, Broeks A, van Thienen JV, Mallo HA, CNS, Adriaansz S, ter Meulen S, Pronk LM, Grijpink-Ongering LG, Bruining A, M.D., Gittelman R, Warren S, van Tinteren H, Peeper D, Haanen JBAG, van Akkooi ACJ, Schumacher TN. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. *Nat Med.* 2018 Nov;24(11):1655-1661
107. Brummer C, Faerber S, Bruss C, **Blank C**, Lacroix R, Haferkamp S, Herr W, Kreutz M, Renner K. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma. *Cancer Lett.* 2019 Feb 1;442:453-463. doi: 10.1016/j.canlet.2018.11.018. Epub 2018 Nov 24.
108. van Kester MS, Luelmo SAC, Vermeer MH, **Blank C**, van Doorn R. Remission of psoriasis during treatment with sorafenib. *JAAD Case Rep.* 2018 Nov 14;4(10):1065-1067. doi: 10.1016/j.jidcr.2018.09.009. eCollection 2018 Nov
109. Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, **Blank CU**, van Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. *JAMA Oncol.* 2018 Dec 13. doi: 10.1001/jamaoncol.2018.5543. [Epub ahead of print]
110. Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hossers G, Lorigan P, Nyakas M, Guminski A, Liskay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, **Blank C**. An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. *Eur J Cancer.* 2018 Dec 20;107:175-185. doi: 10.1016/j.ejca.2018.11.018. [Epub ahead of print]
111. Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi ACJ, van den Braber M, Rozeman EA, Haanen JBAG, **Blank CU**, Horlings HM, David E, Baran Y, Bercovich A, Lifshitz A, Schumacher TN, Tanay A, Amit I. Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. *Cell.* 2019 Feb 7;176(4):775-789

112. Liu J, Rozeman EA, O'Donnell JS, Allen S, Fanchi L, Smyth MJ, **Blank CU**, Teng MWL. Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. *Oncoimmunology*. 2018 Nov 22;8(2):e1546068
113. Wind TT, Jalving M, de Haan JJ, de Vries EGE, van Vugt MATM, Reijngoud DJ, van Rijn RS, Haanen JBAG, **Blank CU**, Hospers GAP, Fehrmann RSN. A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma. *Oncoimmunology*. 2019 Jan 3;8(3):1558664
114. Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, **Blank C**, Weide B. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. *Cancer Immunol Immunother*. 2019 May;68(5):765-772
115. Schermers B, Franke V, Rozeman EA, van de Wiel BA, Bruining A, Wouters MW, van Houdt WJ, Ten Haken B, Muller SH, Bierman C, Ruers TJM, **Blank CU**, van Akkooi ACJ. Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. *Br J Surg*. 2019 Apr;106(5):519-522
116. Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, Călin AM, Pizzi AD, Lalezari F, Lambregts DMJ, Rohaan M, Parmar C, Hartemink KJ, Swanton C, Haanen JBAG, **Blank CU**, Smit EF, Beets-Tan RGH, Aerts HJWL. Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers. *Ann Oncol*. 2019 Mar 21 [Epub ahead of print]
117. Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejbergs L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, **Blank CU**, Neyns B. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. *Ann Oncol*. 2019 Mar 28. [Epub ahead of print]
118. van Herpen CML, Agarwala SS, Hauschild A, Berking C, Beck JT, Schadendorf D, Jansen R, Queirolo P, Ascierto PA, **Blank CU**, Heinrich MC, Pal RR, Derti A, Antona V, Nauwelaerts H, Zube A, Dummer R. Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma. *Oncotarget*. 2019 Mar 5;10(19):1850-1859
119. Bex A, van Thienen JV, Schrier M, Graafland N, Kuusk T, Hendricksen K, Lagerveld B, Zondervan P, van Moorselaar JA, **Blank C**, Wilgenhof S, Haanen J. A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX). *Future Oncol*. 2019 Jul;15(19):2203-2209

120. O'Donnell JS, Hoefsmit EP, Smyth MJ, **Blank CU**, Teng MWL. The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. *Clin Cancer Res.* 2019 Apr 30. [Epub ahead of print]
121. Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, **Blank CU**, Kok M. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. *Nat Med.* 2019 Jun;25(6):920-928. Epub 2019 May 13
122. Bisschop C, Wind TT, **Blank CU**, Koornstra RHT, Kapiteijn E, Van den Eertwegh AJM, De Groot JWB, Jalving M, Hospers GAP. Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program. *J Immunother.* 2019 Jul/Aug;42(6):208-214
123. Rozeman EA, Menzies AM van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Torres Acosta A, ter Meulen S, Koenen AM, Bosch LJ, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Emanuelsson H, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, and **Blank CU**. Identification of a favourable combination scheme of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma: a multicentre randomised phase 2 study (OpACIN-neo). *Lancet Oncol.* 2019 Jul;20(7):948-960
124. Rozeman EA, **Blank CU**. Combining checkpoint inhibition and targeted therapy in melanoma. *Nat Med.* 2019 Jun;25(6):879-882
125. Rogiers A, Boekhout A, Schwarze JK, Awada G, **Blank CU**, Neyns B. Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. *J Oncol.* 2019 Apr 28
126. Eggermont AMM, **Blank CU**, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suci S, Robert C. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. *Eur J Cancer.* 2019 Jul;116:148-157
127. Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, **Blank C**, Larkin J, Garbe C, Schadendorf D, Lorigan P, Schilling B. Efficacy of PD-1-based

immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. *Eur J Cancer*. 2019 Jul;116:207-215

128. De Bruijn RE, Mulders P, Jewett MA, Wagstaff J, Van Thienen JV, **Blank CU**, Van Velthoven R, Wood L, van Melick HE, Aarts MJ, Lattouf JB, Powles T, De Jong IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen JB, Bex A. Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME). *Eur Urol*. 2019 Jun 18
129. Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, **Blank CU**, Tawbi HA, Long GV. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. *Lancet Oncol*. 2019 Jul;20(7):e378-e389
130. Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, Krijgsman O, Huang X, Kenski JCN, Lacroix R, Mezzadra R, Gomez-Eerland R, Yildiz M, Digidir I, Apriamashvili G, Zandhuis N, van der Noort V, Visser NL, **Blank CU**, Altelaar M, Schumacher TN, Peeper DS. Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. *Cell*. 2019 Jul 25;178(3):585-599.e15. 11.
131. Jochems A, van der Kooij MK, Fiocco M, Schouwenburg MG, Aarts MJ, van Akkooi AC, van den Berkmortel FWPJ, **Blank CU**, van den Eertwegh AJM, Franken MG, de Groot JB, Haanen JBAG, Hospers GAP, Koornstra RH, Kruit WHJ, Louwman M, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl MCT, van der Hoeven KJM, Kapiteijn E. Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry. *Cancers* 2019 Jul 18;11(7).
132. Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, **Blank CU**, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. *Lancet Oncol*. 2019 Jul 22. [Epub ahead of print]
133. Hoefsmit EP, Rozeman EA, Haanen JBAG, **Blank CU**. Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. *ESMO Open*. 2019 Jul 21;4(4):e000472. doi: 10.1136/esmoopen-2018-000472.
134. **Blank CU**, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, Schietinger A, Schumacher TN, Schwartzberg PL, Sharpe AH, Speiser DE,

- Wherry EJ, Youngblood BA, Zehn D. Defining 'T cell exhaustion'. *Nat Rev Immunol.* 2019 Nov;19(11):665-674. doi: 10.1038/s41577-019-0221-9. Epub 2019 Sep 30. Review.
135. Renner K, Bruss C, Schnell A, Koehl G, Becker HM, Fante M, Menevse AN, Kauer N, Blazquez R, Hacker L, Decking SM, Bohn T, Faerber S, Evert K, Aigle L, Amslinger S, Landa M, Krijgsman O, Rozeman EA, Brummer C, Siska PJ, Singer K, Pektor S, Miederer M, Peter K, Gottfried E, Herr W, Marchiq I, Pouyssegur J, Roush WR, Ong S, Warren S, Pukrop T, Beckhove P, Lang SA, Bopp T, **Blank CU**, Cleveland JL, Oefner PJ, Dettmer K, Selby M, Kreutz M. Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy. *Cell Rep.* 2019 Oct 1;29(1):135-150.e9. doi: 10.1016/j.celrep.2019.08.068.
136. Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms KM, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, **Blank CU**, Hassel JC. Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. *J Clin Oncol.* 2019 Nov 20;37(33):3142-3151. doi: 10.1200/JCO.19.00489. Epub 2019 Oct 3.
137. Reijers ILM, Rozeman EA, Wilgenhof S, van Thienen JV, Haanen JBAG, **Blank CU**. Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma. *Pigment Cell Melanoma Res.* 2019 Oct 23. doi: 10.1111/pcmr.12835. [Epub ahead of print]
138. Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Amon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, Elmarakeby H, Dietlein F, Miao D, Tracy A, Gogas H, Goldinger SM, Utikal J, **Blank CU**, Rauschenberg R, von Bubnoff D, Krackhardt A, Weide B, Haferkamp S, Kiecker F, Izar B, Garraway L, Regev A, Flaherty K, Paschen A, Van Allen EM, Schadendorf D. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. *Nat Med.* 2019 Dec;25(12):1916-1927.
139. Hauschild A, Ascierto PA, Schadendorf D, Grob JJ, Ribas A, Kiecker F, Dutriaux C, Demidov LV, Lebbé C, Rutkowski P, **Blank CU**, Gutzmer R, Millward M, Kefford R, Haas T, D'Amelio A Jr, Gasal E, Mookerjee B, Chapman PB. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. *Eur J Cancer.* 2020 Jan;125:114-120
140. Eggermont AMM, Kicinski M, **Blank CU**, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suci S. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to

Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol.* 2020 Jan 2

141. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, **Blank CU**, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. *Nature.* 2020 Jan;577(7791):549-555
142. Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, Krijgsman O, Huang X, Kenski JCN, Lacroix R, Mezzadra R, Gomez-Eerland R, Yildiz M, Dagidir I, Apriamashvili G, Zandhuis N, van der Noort V, Visser NL, **Blank CU**, Altelaar M, Schumacher TN, Peeper DS. Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. *Cell.* 2020 Jan 23;180(2):404-405
143. Ugurel S, Schadendorf D, Horny K, Sucker A, Schramm S, Utikal J, Pföhler C, Herbst R, Schilling B, **Blank C**, Becker JC, Paschen A, Zimmer L, Livingstone E, Horn PA, Rebmann V. Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. *Ann Oncol.* 2020 Jan;31(1):144-152
144. Peters MA, Geukes Foppen MH, **Blank CU**, Crijns MB. Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma. *J Cancer Res Ther.* 2020 Jan-Mar;16(1):170-172
145. Versluis JM, Long GV, **Blank CU**. Learning from clinical trials of neoadjuvant checkpoint blockade. *Nat Med.* 2020 Apr;26(4):475-484
146. Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi ACJ, van den Braber M, Rozeman EA, Haanen JBAG, **Blank CU**, Horlings HM, David E, Baran Y, Bercovich A, Lifshitz A, Schumacher TN, Tanay A, Amit I. Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. *Cell.* 2020 Apr 30;181(3):747
147. Verheijden RJ, May AM, **Blank CU**, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, Boers-Sonderen MJ, van der Hoeven JJM, Hospers GA, Piersma D, van Rijn RS, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Haanen JBAG, Kapiteijn E, Suijkerbuijk KPM. Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry. *Clin Cancer Res.* 2020 May 1;26(9):2268-2274

148. Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E, Meltser A, Douglas GM, Kamer I, Gopalakrishnan V, Dadosh T, Levin-Zaidman S, Avnet S, Atlan T, Cooper ZA, Arora R, Cogdill AP, Khan MAW, Ologun G, Bussi Y, Weinberger A, Lotan-Pompan M, Golani O, Perry G, Rokah M, Bahar-Shany K, Rozeman EA, **Blank CU**, Ronai A, Shaoul R, Amit A, Dorfman T, Kremer R, Cohen ZR, Harnof S, Siegal T, Yehuda-Shnaidman E, Gal-Yam EN, Shapira H, Baldini N, Langille MGI, Ben-Nun A, Kaufman B, Nissan A, Golan T, Dadiani M, Levanon K, Bar J, Yust-Katz S, Barshack I, Peeper DS, Raz DJ, Segal E, Wargo JA, Sandbank J, Shental N, Straussman R. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. *Science*. 2020 May 29;368(6494):973-980
149. Rozeman EA, Prevoo W, Meier MAJ, Sikorska K, Van TM, van de Wiel BA, van der Wal JE, Mallo HA, Grijpink-Ongering LG, Broeks A, Lalezari F, Reeves J, Warren S, van Thienen JV, van Tinteren H, Haanen JBAG, Kapiteijn E, **Blank CU**. Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIR-UM). *Melanoma Res*. 2020 Jun;30(3):252-260
150. Haanen JB, **Blank CU**. Prognostic and predictive role of the tumor immune landscape. *J Nucl Med Mol Imaging*. 2020 Jun;64(2):143-151
151. van der Kooij MK, Wetzels MJAL, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Boers-Sonderen MJ, Dierselhuis MP, de Groot JWB, Hospers GAP, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Haanen JBAG, van den Eertwegh AJM, Bastiaannet E, Kapiteijn E. Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. *Cancers (Basel)*. 2020 Jul 27;12(8):2072
152. Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, Mangana J, Atkinson V, Zaman F, Young A, Hoeller C, Hersey P, Dummer R, Khattak MA, Millward M, Patel SP, Haydon A, Johnson DB, Lo S, **Blank CU**, Sandhu S, Carlino MS, Larkin JMG, Menzies AM, Long GV. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. *Ann Oncol*. 2020 Aug;31(8):1075-1082
153. van den Berg JH, Heemskerk B, van Rooij N, Gomez-Eerland R, Michels S, van Zon M, de Boer R, Bakker NAM, Jorritsma-Smit A, van Buuren MM, Kvistborg P, Spits H, Schotte R, Mallo H, Karger M, van der Hage JA, Wouters MWJM, Pronk LM, Geukes Foppen MH, **Blank CU**, Beijnen JH, Nuijen B, Schumacher TN, Haanen JBAG. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. *J Immunother Cancer*. 2020 Aug;8(2):e000848
154. Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, Arance A, **Blank CU**, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Olofsson Bagge R, Puig S, Rutkowski P, Schilling B,

- Sondak VK, Tawbi H, Testori A, Keilholz U. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. *Ann Oncol.* 2020 Aug 4;*S0923-7534(20)39940-3*
155. Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, Arance A, **Blank CU**, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Olofsson Bagge R, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Michielin O. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. *Ann Oncol.* 2020 Aug 4;*S0923-7534(20)39939-7*
156. Boshuizen J, Vredevoogd DW, Krijgsman O, Ligtenberg MA, Blankenstein S, de Bruijn B, Frederick DT, Kenski JCN, Parren M, Brüggemann M, Madu MF, Rozeman EA, Song JY, Horlings HM, **Blank CU**, van Akkooi ACJ, Flaherty KT, Boland GM, Peeper DS. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. *Nat Commun.* 2020 Aug 7;*11(1):3946*
157. Versluis JM, Thommen DS, **Blank CU**. Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach. *J Immunother Cancer.* 2020 Aug;*8(2):e001352*
158. Boekhout AH, Rogiers A, Jozwiak K, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, de Groot JWB, Aarts MJB, Kapiteijn E, Ten Tije AJ, Piersma D, Vreugdenhil G, van der Veldt AA, Suijkerbuijk KPM, Rozeman EA, Neyns B, Janssen KJ, van de Poll-Franse LV, **Blank CU**. Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls. *Acta Oncol.* 2020 Sep 14;*1-9*
159. Eggermont AMM, **Blank CU**, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suci S, Robert C. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. *J Clin Oncol.* 2020 Sep 18
160. Calabrese LH, Caporali R, **Blank CU**, Kirk AD. Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer. *J Autoimmun.* 2020 Sep 23
161. Reijers ILM, Hilhorst M, Tan M, Klarenbeek PL, Hak AE, **Blank CU**. Acrocyanosis after neoadjuvant ipilimumab plus nivolumab: a case report. *Clin Exp Rheumatol.* 2020 Sep-Oct;*38(5):1031-1032*

162. van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, van Montfoort ML, van Rooijen C, Peters D, Broeks A, van der Poel HG, Bruining A, Lubeck Y, Sikorska K, Boellaard TN, Kvistborg P, Vis DJ, Hooijberg E, Schumacher TN, van den Broek M, Wessels LFA, **Blank CU**, van Rhijn BW, van der Heijden MS. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. *Nat Med.* 2020 Oct 12
163. Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA, Zimmer L, Schadendorf D, Allayous C, Lebbe C, Maurichi A, Santinami M, Roy S, Robert C, Lesimple T, Patel S, Versluis JM, **Blank CU**, Khattak A, Van der Westhuizen A, Carlino MS, Shackleton M, Haydon A. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. *Br J Cancer.* 2020 Oct 22
164. Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA, Zimmer L, Schadendorf D, Allayous C, Lebbe C, Maurichi A, Santinami M, Roy S, Robert C, Lesimple T, Patel S, Versluis JM, **Blank CU**, Khattak A, Van der Westhuizen A, Carlino MS, Shackleton M, Haydon A. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. *Br J Cancer.* 2021 Feb;124(3):574-580
165. Mueller KL, Theoret MR, Lemery SJ, Amiri-Kordestani L, Ariyan CE, Atkins MB, Berry DA, **Blank CU**, DeMichele AM, Forde PM, Ibrahim N, Keegan P, Mitchell TC, Moss RA, Robert C, Sridhara R, Taube JM, Tetzlaff MT, Wargo JA, Flaherty KT, Kaplan MJ, Topalian SL, Ward AF, Hurlbert MS. Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop. *Clin Cancer Res.* 2021 Jan 15;27(2):394-401
166. Verheijden RJ, May AM, **Blank CU**, van der Veldt AAM, Boers-Sonderen MJ, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, van der Hoeven JJM, Hospers GAP, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Haanen JBAG, Kapiteijn E, Suijkerbuijk KPM. Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. *ESMO Open.* 2020 Nov;5(6)
167. Hoefsmit EP, Rozeman EA, Van TM, Dimitriadis P, Krijgsman O, Conway JW, Pires da Silva I, van der Wal JE, Ketelaars SLC, Bresser K, Broeks A, Kerkhoven RM, Reeves JW, Warren S, Kvistborg P, Scolyer RA, Kapiteijn EW, Peeper DS, Long GV, Schumacher TNM, **Blank CU**. Comprehensive analysis of cutaneous and uveal melanoma liver metastases. *J Immunother Cancer.* 2020 Dec;8(2)
168. Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose AAN, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupu J, Vaisman A, Saibil SD, Butler MO, Menzies AM, Carlino MS, Erdmann M, Berking C, Zimmer L, Schadendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, **Blank CU**, Robert C, Sullivan RJ, Ascierto PA, Miller WH Jr, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma

- OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. *J Immunother Cancer*. 2021 Jan
169. Rao D, Verburg F, Renner K, Peeper DS, Lacroix R, **Blank CU**. Metabolic profiles of regulatory T cells in the tumour microenvironment. *Cancer Immunol Immunother*. 2021 Feb
170. van Breeschoten J, Wouters MWJM, de Wreede LC, Hilarius DH, Haanen JB, **Blank CU**, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokkx WAM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Boers MJ, van den Eertwegh AJM. Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status. *Am J Clin Oncol*. 2021 Feb
171. Rozeman EA, Hoefsmit EP, Reijers ILM, Saw RPM, Versluis JM, Krijgsman O, Dimitriadis P, Sikorska K, van de Wiel BA, Eriksson H, Gonzalez M, Torres Acosta A, Griepink-Ongering LG, Shannon K, Haanen JBAG, Stretch J, Ch'ng S, Nieweg OE, Mallo HA, Adriaansz S, Kerkhoven RM, Cornelissen S, Broeks A, Klop WMC, Zuur CL, van Houdt WJ, Peeper DS, Spillane AJ, van Akkooi ACJ, Scolyer RA, Schumacher TNM, Menzies AM, Long GV, **Blank CU**. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. *Nat Med*. 2021 Feb;27(2):256-263.
172. van der Kooij MK, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Boers-Sonderen MJ, van Breeschoten J, van den Eertwegh AJM, B de Groot JW, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Dekkers OM, Kapiteijn E. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study. *Ann Intern Med*. 2021 Feb
173. Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, Ascierto PA, Spillane AJ, van Akkooi ACJ, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, **Blank CU**, Long GV. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). *Nat Med*. 2021 Feb;27(2):301-309
174. van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, **Blank CU**, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokkx WAM, Tije BJT, Veldt AAMV, Vreugdenhil A, Boers-Sonderen MJ, van den Eertwegh AJM. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. *Br J Cancer*. 2021 Mar;124(7):1222-1230
175. Rawson RV, Adhikari C, Bierman C, Lo SN, Shklovskaya E, Rozeman EA, Menzies AM, van Akkooi ACJ, Shannon KF, Gonzalez M, Guminski AD, Tetzlaff MT, Stretch JR, Eriksson H, van Thienen JV, Wouters MW, Haanen JBAG, Klop WMC, Zuur CL, van

- Houdt WJ, Nieweg OE, Ch'ng S, Rizos H, Saw RPM, Spillane AJ, Wilmott JS, **Blank CU**, Long GV, van de Wiel BA, Scolyer RA. Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. *Ann Oncol.* 2021 Mar 17
176. Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, Martínez-Vila C, Wallace R, Bhave P, Reijers I, Thompson N, Vanella V, Gerard C, Aspeslagh S, Labianca A, Khattak A, Mandala M, Xu W, Neyns B, Michielin O, **Blank CU**, Welsh SJ, Haydon A, Sandhu S, Mangana J, McQuade JL, Ascierto PA, Zimmer L, Johnson DB, Arance A, Lorigan P, Lebbé C, Carlino MS, Sullivan R, Long GV, Menzies AM. Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma. *Ann Oncol.* 2021 Mar 30
177. van der Veldt AAM, Oosting SF, Dingemans AC, Fehrmann RSN, GeurtsvanKessel C, Jalving M, Rimmelzwaan GF, Kvistborg P, **Blank CU**, Smit EF, Lemmens VEEP, Hiltermann TJN, Koopmans MPG, Huckriede ALW, Rots NY, van Els CACM, van Baarle D, Haanen JBAG, de Vries EGE. COVID-19 vaccination: the VOICE for patients with cancer. *Nat Med.* 2021 Apr;27(4):568-569
178. Blankenstein SA, Rohaan MW, Klop WMC, van der Hiel B, van de Wiel BA, Lahaye MJ, Adriaansz S, Sikorska K, van Tinteren H, Sari A, Grijpink-Ongering LG, van Houdt WJ, Wouters MWJM, **Blank CU**, Wilgenhof S, van Thienen JV, van Akkooi ACJ, Haanen JBAG. Neoadjuvant Cytoreductive Treatment with BRAF/MEK Inhibition of prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single Arm, Open-label Phase II Trial. *Ann Surg.* 2021 Apr 9
179. Eggermont AMM, **Blank CU**, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciú S, Robert C; EORTC Melanoma Group. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncol.* 2021 May;22(5):643-654
180. Bottomley A, Coens C, Mierzynska J, **Blank CU**, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciú S, Robert C, Eggermont AMM; EORTC Melanoma Group. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncol.* 2021 May;22
181. Versluis JM, Reijers ILM, Rozeman EA, Menzies AM, van Akkooi ACJ, Wouters MW, Ch'ng S, Saw RPM, Scolyer RA, van de Wiel BA, Schilling B, Long GV, **Blank CU**.

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. *Eur J Cancer*. 2021 May;148:51-57.

182. Rawson RV, Adhikari C, Bierman C, Lo SN, Shklovskaya E, Rozeman EA, Menzies AM, van Akkooi ACJ, Shannon KF, Gonzalez M, Guminski AD, Tetzlaff MT, Stretch JR, Eriksson H, van Thienen JV, Wouters MW, Haanen JBAG, Klop WMC, Zuur CL, van Houdt WJ, Nieweg OE, Ch'ng S, Rzos H, Saw RPM, Spillane AJ, Wilmott JS, **Blank CU**, Long GV, van de Wiel BA, Scolyer RA. Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. *Ann Oncol*. 2021 Jun;32(6):766-777
183. Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, **Blank CU**, Menzies AM, Long GV. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. *Lancet Oncol*. 2021 Jun;22(6):836-847
184. de Glas NA, Bastiaannet E, van den Bos F, Mooijaart SP, van der Veldt AAM, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JB, Haanen JBAG, Hospers GAP, Jalving H, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, Portielje JEA, Kapiteijn EW. Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. *Cancers (Basel)*. 2021 Jun 5;13(11):2826
185. Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, Martínez-Vila C, Wallace R, Bhave P, Reijers ILM, Thompson N, Vanella V, Gerard CL, Aspeslagh S, Labianca A, Khattak A, Mandala M, Xu W, Neyns B, Michielin O, **Blank CU**, Welsh SJ, Haydon A, Sandhu S, Mangana J, McQuade JL, Ascierto PA, Zimmer L, Johnson DB, Arance A, Lorigan P, Lebbé C, Carlino MS, Sullivan RJ, Long GV, Menzies AM. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. *Ann Oncol*. 2021 Jul;32(7):917-925
186. Krijgsman O, Kemper K, Boshuizen J, Vredevoogd DW, Rozeman EA, Ibanez Molero S, de Bruijn B, Cornelissen-Steijger P, Shahrabi A, Del Castillo Velasco-Herrera M, Song JY, Ligtenberg MA, Kluin RJC, Kuilman T, Ross-Macdonald P, Haanen JBAG, Adams DJ, **Blank CU**, Peeper DS. Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4. *Clin Cancer Res*. 2021 Jul 6
187. Versluis JM, Hendriks AM, Weppler AM, Brown LJ, de Joode K, Suijkerbuijk KPM, Zimmer L, Kapiteijn EW, Allayous C, Johnson DB, Hepner A, Mangana J, Bhave P, Jansen YJL, Trojaniello C, Atkinson V, Storey L, Lorigan P, Ascierto PA, Neyns B, Haydon A, Menzies AM, Long GV, Lebbe C, van der Veldt AAM, Carlino MS, Sandhu S, van Tinteren H, de Vries EGE, **Blank CU**, Jalving M. The role of local therapy in the treatment of

solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. *Eur J Cancer*. 2021 Jul;151:72-83

188. Voabil P, de Bruijn M, Roelofsen LM, Hendriks SH, Brokamp S, van den Braber M, Broeks A, Sanders J, Herzig P, Zippelius A, **Blank CU**, Hartemink KJ, Monkhorst K, Haanen JBAG, Schumacher TN, Thommen DS. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. *Nat Med*. 2021 Jul;27(7):1250-1261
189. Blankenstein SA, Rohaan MW, Klop WMC, van der Hiel B, van de Wiel BA, Lahaye MJ, Adriaansz S, Sikorska K, van Tinteren H, Sari A, Grijpink-Ongering LG, van Houdt WJ, Wouters MWJM, **Blank CU**, Wilgenhof S, van Thienen JV, van Akkooi ACJ, Haanen JBAG. Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial. *Ann Surg*. 2021 Aug 1;274(2):383-389
190. Suijkerbuijk KPM, Haanen JBAG, Boers-Sonderen MJ, Hospers GAP, **Blank CU**, van den Berkmortel FWPJ, de Groot JWB, Piersma D, Aarts MJB, van Rijn RS, Vreugdenhil G, Westgeest HM, Kapiteijn E, van der Veldt AAM, van den Eertwegh AJM. Survival of stage IV melanoma in Belgium and the Netherlands. *J Eur Acad Dermatol Venereol*. 2021 Sep 18
191. van Breeschoten J, van den Eertwegh AJM, de Wreede LC, Hilarius DL, van Zwet EW, Haanen JB, **Blank CU**, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Suijkerbuijk KPM, Wouters MWJM. Hospital Variation in Cancer Treatments and Survival Outcomes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. *Cancers (Basel)*. 2021 Oct 11;13(20):5077. doi: 10.3390/cancers13205077
192. Eggermont AM, Meshcheryakov A, Atkinson V, **Blank CU**, Mandala M, Long GV, Barrow C, Di Giacomo AM, Fisher R, Sandhu S, Kudchadkar R, Ortiz Romero PL, Svane IM, Larkin J, Puig S, Hersey P, Quaglino P, Queirolo P, Stroyakovskiy D, Bastholt L, Mohr P, Hernberg M, Chiarion-Sileni V, Strother M, Hauschild A, Yamazaki N, van Akkooi AC, Lorigan P, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suci S, Robert C. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. *Eur J Cancer*. 2021 Oct 18;158:156-168. doi: 10.1016/j.ejca.2021.09.023
193. Gangaev A, Rozeman EA, Rohaan MW, Isaeva OI, Philips D, Patiwaal S, van den Berg JH, Ribas A, Schadendorf D, Schilling B, Schumacher TN, **Blank CU**, Haanen JBAG, Kvistborg P. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. *Proc Natl Acad Sci U S A*. 2021 Oct 26;118(43):e2102849118. doi: 10.1073/pnas.2102849118

194. de Meza MM, Ismail RK, Rauwerdink D, van Not OJ, van Breeschoten J, Blokx WAM, de Boer A, van Dartel M, Hilarius DL, Ellebaek E, Bonenkamp HJ, **Blank CU**, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB, Haanen JB, Hospers GAP, Kapiteijn EW, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil A, Westgeest HM, van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. Adjuvant treatment for melanoma in clinical practice - Trial versus reality. *Eur J Cancer*. 2021 Nov;158:234-245. doi: 10.1016/j.ejca.2021.08.044
195. Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, Fehrmann RSN, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, Westphal TT, Bhattacharya A, van der Heiden M, Rimmelzwaan GF, Kvistborg P, **Blank CU**, Koopmans MPG, Huckriede ALW, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. *Lancet Oncol*. 2021 Dec;22(12):1681-1691. doi: 10.1016/S1470-2045(21)00574-X
196. Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, Lubeck Y, Seignette IM, Smit LA, Willems SM, van den Brekel MWM, Dirven R, Baris Karakullukcu M, Karssemakers L, Klop WMC, Lohuis PJFM, Schreuder WH, Smeele LE, van der Velden LA, Bing Tan I, Onderwater S, Jasperse B, Vogel WV, Al-Mamgani A, Keijser A, van der Noort V, Broeks A, Hooijberg E, Peeper DS, Schumacher TN, **Blank CU**, de Boer JP, Haanen JBAG, Zuur CL. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. *Nat Commun*. 2021 Dec 22;12(1):7348. doi: 10.1038/s41467-021-26472-9
197. **Blank CU**, Wong DJ, Ho TH, Bauer TM, Lee CB, Bene-Tchaleu F, Zhu J, Zhang X, Cha E, Sznol M. Phase Ib Study of Atezolizumab Plus Interferon- α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. *Curr Oncol*. 2021 Dec 20;28(6):5466-5479. doi: 10.3390/curroncol28060455
198. Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, **Blank CU**, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. *Cancer Cell*. 2022 Jan 10;40(1):88-102.e7. doi: 10.1016/j.ccell.2021.11.012
199. Meerveld-Eggink A, Graafland N, Wilgenhof S, Van Thienen JV, Lalezari F, Grant M, Szabados B, Abu-Ghanem Y, Kuusk T, Boleti E, **Blank CU**, Haanen JBAG, Powles T, Bex A. Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment. *Eur Urol Open Sci*. 2022 Jan 3;35:54-58. doi: 10.1016/j.euro.2021.11.003

200. Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, Lubeck Y, Seignette IM, Smit LA, Willems SM, van den Brekel MWM, Dirven R, Baris Karakullukcu M, Karssemakers L, Klop WMC, Lohuis PJFM, Schreuder WH, Smeele LE, van der Velden LA, Bing Tan I, Onderwater S, Jasperse B, Vogel WV, Al-Mamgani A, Keijser A, van der Noort V, Broeks A, Hooijberg E, Peeper DS, Schumacher TN, **Blank CU**, de Boer JP, Haanen JBAG, Zuur CL. *Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat Commun. 2021 Dec 22;12(1):7348. doi: 10.1038/s41467-021-26472-9. PMID: 34937871 Free PMC article. Clinical Trial*
201. van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, **Blank CU**, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Olofsson Bagge R, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI; International Neoadjuvant Melanoma Consortium (INMC). Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). *Ann Surg Oncol. 2022 Jan 28. doi: 10.1245/s10434-021-11236-y*
202. Tong TML, van der Kooij MK, Speetjens FM, van Erkel AR, van der Meer RW, Lutjeboer J, van Persijn van Meerten EL, Martini CH, Zoethout RWM, Tijl FGJ, **Blank CU**, Burgmans MC, Kapiteijn E. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial. *Trials. 2022 Feb 13;23(1):137. doi: 10.1186/s13063-022-06036-y*
203. van Not OJ, van Breeschoten J, van den Eertwegh AJM, Hilarius DL, De Meza MM, Haanen JB, **Blank CU**, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Ismail RK, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Blokk WAM, Suijkerbuijk KPM, Wouters MWJM. The unfavorable effects of COVID-19 on Dutch advanced melanoma care. *Int J Cancer. 2022 Mar 1;150(5):816-824. doi: 10.1002/ijc.33833*
204. Reijers ILM, Rawson RV, Colebatch AJ, Rozeman EA, Menzies AM, van Akkooi ACJ, Shannon KF, Wouters MW, Saw RPM, van Houdt WJ, Zuur CL, Nieweg OE, Ch'ng S, Klop WMC, Spillane AJ, Long GV, Scolyer RA, van de Wiel BA, **Blank CU**. Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. *JAMA Surg. 2022 Apr 1;157(4):335-342. doi: 10.1001/jamasurg.2021.7554*
205. Pires da Silva I, Ahmed T, McQuade JL, Nebhan CA, Park JJ, Versluis JM, Serra-Bellver P, Khan Y, Slattery T, Oberoi HK, Ugurel S, Haydu LE, Herbst R, Utikal J, Pföhler C, Terheyden P, Weichenthal M, Gutzmer R, Mohr P, Rai R, Smith JL, Scolyer RA, Arance AM, Pickering L, Larkin J, Lorigan P, **Blank CU**, Schadendorf D, Davies MA, Carlino MS, Johnson DB, Long GV, Lo SN, Menzies AM. Clinical Models to Define Response and

Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. *J Clin Oncol.* 2022 Apr 1;40(10):1068-1080. doi: 10.1200/JCO.21.01701

206. Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciuc S, **Blank CU**, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. Prognostic and predictive value of β -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. *Eur J Cancer.* 2022 Apr;165:97-112. doi: 10.1016/j.ejca.2022.01.017
207. van Not OJ, de Meza MM, van den Eertwegh AJM, Haanen JB, **Blank CU**, Aarts MJB, van den Berkmortel FWPJ, van Breeschoten J, de Groot JB, Hospers GAP, Ismail RK, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Bonenkamp HJ, Boers-Sonderen MJ, Blokx WAM, Wouters MWJM, Suijkerbuijk KPM. Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study. *Eur J Cancer.* 2022 Apr 4;167:70-80. doi: 10.1016/j.ejca.2022.02.026
208. Kaptein P, Jacobberger-Foissac C, Dimitriadis P, Voabil P, de Bruijn M, Brokamp S, Reijers I, Versluis J, Nallan G, Triscott H, McDonald E, Tay J, Long GV, **Blank CU**, Thommen DS, Teng MWL. Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors. *Sci Transl Med.* 2022 Apr 27;14(642):eabj9779. doi: 10.1126/scitranslmed.abj9779
209. Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, **Blank CU**, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel JC, Ugurel S, Zimmer L, Banks P, Spain L, Soon JA, Enokida T, Tahara M, Kähler KC, Seggewiss-Bernhardt R, Harvey C, Long GV, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French LE, Knauss S, Heinzerling LM. *Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.* *Data Brief.* 2022;45:108649
210. Ismail RK, Suijkerbuijk KPM, de Boer A, van Dartel M, Hilarius DL, Pasmooij AMG, van Zeijl MCT, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Boers-Sonderen MJ, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil A, Westgeest H, van den Eertwegh AJ, Wouters MWJM. *Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.* *Melanoma Res.* 2022;32:460-8
211. Rauwerdink DJW, van Doorn R, van der Hage J, Van den Eertwegh AJM, Haanen JBAG, Aarts M, Berkmortel F, **Blank CU**, Boers-Sonderen MJ, De Groot JWB, Hospers GAP, de Meza M, Piersma D, Van Rijn RS, Stevense M, Van der Veldt A, Vreugdenhil G, Wouters MWJM, Suijkerbuijk K, van der Kooij M, Kapiteijn E. *Systemic Therapy in Advanced Nodular*

Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry. Cancers (Basel). 2022;14:5694

212. Blankenstein SA, Bonenkamp JJ, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Blokk WAM, Boers-Sonderen MJ, van den Eertwegh AJM, Franken MG, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, van Akkooi ACJ. *ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease? Ann Surg Oncol. 2022;1*
213. Serra-Bellver P, Versluis JM, Oberoi HK, Zhou C, Slattery TD, Khan Y, Patrinely JR, Pires da Silva I, Martínez-Vila C, Cook N, Graham DM, Carlino MS, Menzies AM, Arance AM, Johnson DB, Long GV, Pickering L, Larkin JMG, **Blank CU**, Lorigan P. *Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. Eur J Cancer. 2022;176:121-132*
214. Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, **Blank CU**, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel JC, Ugurel S, Zimmer L, Banks P, Spain L, Soon JA, Enokida T, Tahara M, Kähler KC, Seggewiss-Bernhardt R, Harvey C, Long GV, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French LE, Knauss S, Heinzerling LM. *Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. Eur J Cancer. 2022;175:224-35*
215. Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, Versluis JM, Ribeiro R, Angelatos AS, Tan J, Adhikari C, Menzies AM, Saw RPM, Gonzalez M, Shannon KF, Spillane AJ, Velickovic R, Lazar AJ, Damania AV, Mishra AK, Chelvanambi M, Banerjee A, Ajami NJ, Wargo JA, Macia L, Holmes AJ, Wilmott JS, **Blank CU**, Scolyer RA, Long GV. *Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat Med. 2022;28:2344-52*
216. van Not OJ, Verheijden RJ, van den Eertwegh AJM, Haanen JBAG, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Boers-Sonderen MJ, de Groot JB, Hospers GAP, Kamphuis AM, Kapiteijn E, May AM, de Meza MM, Piersma D, van Rijn R, Stevense-den Boer MA, van der Veldt AAM, Vreugdenhil G, Blokk WAM, Wouters MJM, Suijkerbuijk KPM. *Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma. JAMA Oncol. 2022;27*
217. Blankenstein SA, Bonenkamp JJ, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Blokk WAM, Boers-Sonderen MJ, van den Eertwegh AJM, Franken MG, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, van Akkooi ACJ. *Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant*

Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease? Ann Surg Oncol. 2022;6

218. van Breeschoten J, Ismail RK, Wouters MWJM, Hilarius DL, de Wreede LC, Haanen JB, **Blank CU**, Aarts MJB, van den Bergmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MA, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Suijkerbuijk KPM, van den Eertwegh AJM. *End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study. JCO Oncol Pract. 2022;18*
219. van Not OJ, Blokk WAM, van den Eertwegh AJM, de Meza MM, Haanen JB, **Blank CU**, Aarts MJB, van den Bergmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer M, van der Veldt AAM, Boers-Sonderen MJ, Jansen AML, Wouters MWJM, Suijkerbuijk KPM. *BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma. JCO Precis Oncol. 2022 Sep;6*
220. Rohaan MW, Gomez-Eerland R, van den Berg JH, Geukes Foppen MH, van Zon M, Raud B, Jedema I, Scheij S, de Boer R, Bakker NAM, van den Broek D, Pronk LM, Grijpink-Ongering LG, Sari A, Kessels R, van den Haak M, Mallo HA, Karger M, van de Wiel BA, Zuur CL, Duinkerken CW, Lalezari F, van Thienen JV, Wilgenhof S, **Blank CU**, Beijnen JH, Nuijen B, Schumacher TN, Haanen JBAG. *MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial. Immunooncol Technol. 2022;18*
221. Dimitriou F, Namikawa K, Reijers ILM, Buchbinder EI, Soon JA, Zaremba A, Teterycz P, Mooradian MJ, Armstrong E, Nakamura Y, Vitale MG, Tran LE, Bai X, Allayous C, Provent-Roy S, Indini A, Bhave P, Farid M, Kähler KC, Mehmi I, Atkinson V, Klein O, Stonesifer CJ, Zaman F, Haydon A, Carvajal RD, Hamid O, Dummer R, Hauschild A, Carlino MS, Mandala M, Robert C, Lebbe C, Guo J, Johnson DB, Ascierto PA, Shoushtari AN, Sullivan RJ, Cybulska-Stopa B, Rutkowski P, Zimmer L, Sandhu S, **Blank CU**, Lo SN, Menzies AM, Long GV. *Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Ann Oncol. 2022;33:968-80*
222. Rozeman EA, Versluis JM, Moritz R, Wilgenhof S, van Thienen JV, Haanen JBAG, van de Heuvel MM, **Blank CU**, van Rossum HH. *Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma. Clin Chim Acta. 2022;1*
223. van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, **Blank CU**, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Bagge RO, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI; *International Neoadjuvant Melanoma Consortium (INMC). Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant*

224. Bhave P, Ahmed T, Lo SN, Shoushtari A, Zaremba A, Versluis JM, Mangana J, Weichenthal M, Si L, Lesimple T, Robert C, Trojanello C, Wicky A, Heywood R, Tran L, Batty K, Dimitriou F, Stansfeld A, Allayous C, Schwarze JK, Mooradian MJ, Klein O, Mehmi I, Roberts-Thomson R, Maurichi A, Yeoh HL, Khattak A, Zimmer L, **Blank CU**, Ramelyte E, Kähler KC, Roy S, Ascierto PA, Michielin O, Lorigan PC, Johnson DB, Plummer R, Lebbe C, Neyns B, Sullivan R, Hamid O, Santinami M, McArthur GA, Haydon AM, Long GV, Menzies AM, Carlino MS. *Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.* *J Immunother Cancer.* 2022 Jul;10(7):e004668. doi: 10.1136/jitc-2022-004668. PMID: 35793872 Free PMC article
225. Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, Pennington TE, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Hospers GAP, Rozeman EA, Klop WMC, van Houdt WJ, Sikorska K, van der Hage JA, Grünhagen DJ, Wouters MW, Witkamp AJ, Zuur CL, Lijnsvelt JM, Torres Acosta A, Grijpink-Ongering LG, Gonzalez M, Józwiak K, Bierman C, Shannon KF, Ch'ng S, Colebatch AJ, Spillane AJ, Haanen JBAG, Rawson RV, van de Wiel BA, van de Poll-Franse LV, Scolyer RA, Boekhout AH, Long GV, **Blank CU**. *Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.* *Nat Med.* 2022 Jun;28(6):1178-1188.
226. van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, **Blank CU**, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grünhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Olofsson Bagge R, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI. *International Neoadjuvant Melanoma Consortium (INMC). Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).* *Ann Surg Oncol.* 2022 Jun;29(6):3694-3708. doi: 10.1245/s10434-021-11236-y. Epub 2022 Jan 28. PMID: 35089452
227. van Not OJ, de Meza MM, van den Eertwegh AJM, Haanen JB, **Blank CU**, Aarts MJB, van den Bergmortal FWPJ, van Breeschoten J, de Groot JB, Hospers GAP, Ismail RK, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Bonenkamp HJ, Boers-Sonderen MJ, Blokx WAM, Wouters MWJM, Suijkerbuijk KPM. *Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study.* *Eur J Cancer.* 2022 May;167:70-80. doi: 10.1016/j.ejca.2022.02.026. Epub 2022 Apr 5. PMID: 35395553
228. van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, **Blank CU**, Aarts MJB, van den Bergmortal FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Tije BJT, Veldt AAMV, Vreugdenhil A, Boers-Sonderen MJ, van den Eertwegh AJM. *Correction: First-line BRAF/MEK inhibitors versus anti-PD-1*

- monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. Br J Cancer. 2022 May;126(9):1362. doi: 10.1038/s41416-022-01772-z. PMID: 35256756 Free PMC article. No abstract available*
229. Kaptein P, Jacobberger-Foissac C, Dimitriadis P, Voabil P, de Bruijn M, Brokamp S, Reijers I, Versluis J, Nallan G, Triscott H, McDonald E, Tay J, Long GV, **Blank CU**, Thommen DS, Teng MWL. *Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors. Sci Transl Med. 2022 Apr 27;14(642):eabj9779. doi: 10.1126/scitranslmed.abj9779. Epub 2022 Apr 27. PMID: 35476594*
230. Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suci S, **Blank CU**, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. *Prognostic and predictive value of β -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer. 2022 Apr;165:97-112. doi: 10.1016/j.ejca.2022.01.017. Epub 2022 Feb 24. PMID: 35220182 Clinical Trial*
231. Pires da Silva I, Ahmed T, McQuade JL, Nebhan CA, Park JJ, Versluis JM, Serra-Bellver P, Khan Y, Slattery T, Oberoi HK, Ugurel S, Haydu LE, Herbst R, Utikal J, Pföhler C, Terheyden P, Weichenthal M, Gutzmer R, Mohr P, Rai R, Smith JL, Scolyer RA, Arance AM, Pickering L, Larkin J, Lorigan P, **Blank CU**, Schadendorf D, Davies MA, Carlino MS, Johnson DB, Long GV, Lo SN, Menzies AM. *Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. J Clin Oncol. 2022 Apr 1;40(10):1068-1080. doi: 10.1200/JCO.21.01701. Epub 2022 Feb 10. PMID: 35143285*
232. Reijers ILM, Rawson RV, Colebatch AJ, Rozeman EA, Menzies AM, van Akkooi ACJ, Shannon KF, Wouters MW, Saw RPM, van Houdt WJ, Zuur CL, Nieweg OE, Ch'ng S, Klop WMC, Spillane AJ, Long GV, Scolyer RA, van de Wiel BA, **Blank CU**. *Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. JAMA Surg. 2022 Apr 1;157(4):335-342. doi:10.1001/jamasurg.2021.7554. PMID: 35138335 Clinical Trial*
233. van Not OJ, van Breeschoten J, van den Eertwegh AJM, Hilarius DL, De Meza MM, Haanen JB, **Blank CU**, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Ismail RK, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Blokk WAM, Suijkerbuijk KPM, Wouters MWJM. *The unfavorable effects of COVID-19 on Dutch advanced melanoma care. Int J Cancer. 2022 Mar 1;150(5):816-824. doi: 10.1002/ijc.33833. Epub 2021 Oct 22. PMID: 34605003 Free PMC article*

234. Tong TML, van der Kooij MK, Speetjens FM, van Erkel AR, van der Meer RW, Lutjeboer J, van Persijn van Meerten EL, Martini CH, Zoethout RWM, Tijl FGJ, **Blank CU**, Burgmans MC, Kapiteijn E. *Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial. Trials.* 2022 Feb 13;23(1):137. doi: 10.1186/s13063-022-06036-y.PMID: 35152908 Free PMC article
235. Suijkerbuijk KPM, Haanen JBAG, Boers-Sonderen MJ, Hospers GAP, **Blank CU**, van den Berkmortel FWPJ, de Groot JWB, Piersma D, Aarts MJB, van Rijn RS, Vreugdenhil G, Westgeest HM, Kapiteijn E, van der Veldt AAM, van den Eertwegh AJM. *Survival of stage IV melanoma in Belgium and the Netherlands. J Eur Acad Dermatol Venereol.* 2022 Feb;36(2):e118-e119. doi: 10.1111/jdv.17668. Epub 2021 Sep 30. PMID: 34536304 No abstract available.
236. Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, **Blank CU**, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV. *Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell.* 2022 Jan 10;40(1):88-102.e7. doi: 10.1016/j.ccell.2021.11.012. Epub 2021 Dec 23. PMID: 34951955
237. Meerveld-Eggink A, Graafland N, Wilgenhof S, Van Thienen JV, Lalezari F, Grant M, Szabados B, Abu-Ghanem Y, Kuusk T, Boleti E, **Blank CU**, Haanen JBAG, Powles T, Bex A. *Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment. Eur Urol Open Sci.* 2022 Jan 3;35:54-58. doi: 10.1016/j.euro.2021.11.003. eCollection 2022 Jan. PMID: 35024632 Free PMC article
238. M.W. Rohaan, T.H. Borch, J.H. van den Berg, O. Met, R. Kessels, M.H. Geukes Foppen, J. Stoltenborg Granhoj, B. Nuijen, C. Nijenhuis, I. Jedema, M. van Zon, S. Scheij, J.H. Beijnen, M. Hansen, C. Voermans, I.M. Noringriis, T.J. Monberg, R.B. Holmstroem, L.D.V. Wever, M. van Dijk, L.G. Griepink-Ongering, L.H.M. Valkenet, A. Torres Acosta, M. Karger, J.S.W. Borgers, R.M.T. ten Ham, V.P. Retel, W.H. van Harten, F. Lalezari, H. van Tinteren, A.A.M. van der Veldt, G.A.P. Hospers, M.A.M. Stevense-den Boer, K.P.M. Suijkerbuijk, M.J.B. Aarts, D. Piersma, A.J.M. van den Eertwegh, J.-W.B. de Groot, G. Vreugdenhil, E. Kapiteijn, M.J. Boers-Sonderen, W.E. Fiets, F.W.P.J. van den Berkmortel, E. Ellebaek, L.R. Holmich, A.C.J. van Akkooi, W.J. van Houdt, M.W.J.M. Wouters, J.V. van Thienen, **C.U. Blank**, A. Meerveld-Eggink, S. Klobuch, S. Wilgenhof, T.N. Schumacher, M. Donia, I.M. Svane, and J.B.A.G. Haanen. *Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med* 2022;387:2113-25
239. Borgers JSW, Burgers FH, Terveer EM, van Leerdam ME, Korse CM, Kessels R, Flohil CC, **Blank CU**, Schumacher TN, van Dijk M, Henderickx JGE, Keller JJ, Verspaget HW, Kuijper EJ, Haanen JBAG. *Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial. BMC Cancer.* 2022 Dec 30;22(1):1366

240. De Meza MM, Blokk WAM, Bonenkamp JJ, **Blank CU**, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, De Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Van Not OJ, Piersma D, Van Rijn RS, Stevense-den Boer M, Van der Veldt AAM, Vreugdenhil G, Van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. *Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis*. *Cancers (Basel)*. 2023 Jan 7;15(2):409
241. Rao D, Lacroix R, Rooker A, Gomes T, Stunnenberg JA, Valenti M, Dimitriadis P, Lin CP, de Bruijn B, Krijgsman O, Ligtenberg MA, Peeper DS, **Blank CU**. *MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance*. *Melanoma Res*. 2023 Feb 1;33(1):12-26
242. Helderma NC, Lucas MW, **Blank CU**. *Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors*. *Immuno-oncol Technol*. 2023 Feb 11;17:100374
243. Boer FL, Ho VKY, Louwman MWJ, Schrader AMR, Zuur CL, **Blank CU**, van Poelgeest MIE, Kapiteijn EHW. *Trends in Incidence and Survival of 1496 Patients with Mucosal Melanoma in The Netherlands (1990-2019)*. *Cancers (Basel)*. 2023 Feb 28;15(5):1541
244. van der Kooij MK, Joosse A, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, Dekkers OM, Kapiteijn E. *Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study*. *Br J Cancer*. 2023 Mar;128(5):707-710
245. Tong TML, Burgmans MC, Speetjens FM, van Erkel AR, van der Meer RW, van Rijswijk CSP, Jonker-Bos MA, Roozen CFM, Sporrel-Blokland M, Lutjeboer J, van Persijn van Meerten EL, Martini CH, Zoethout RWM, Tijl FGJ, **Blank CU**, Kapiteijn E. *Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial*. *Cardiovasc Intervent Radiol*. 2023 Mar;46(3):350-359
246. van Breeschoten J, van den Eertwegh AJM, Hilarius DL, Haanen JB, **Blank CU**, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MA, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Manevski D, Suijkerbuijk KPM, Wouters MWJM, de Wreede LC. *Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry*. *Eur J Cancer*. 2023 Mar;182:132-143
247. Versluis JM, Menzies AM, Sikorska K, Rozeman EA, Saw RPM, van Houdt WJ, Eriksson H, Klop WMC, Ch'ng S, van Thienen JV, Mallo H, Gonzalez M, Torres Acosta A, Grijpink-Ongering LG, van der Wal A, Bruining A, van de Wiel BA, Scolyer RA, Haanen JBAG, Schumacher TN, van Akkooi ACJ, Long GV, **Blank CU**. *Survival update of neoadjuvant*

ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol. 2023 Apr;34(4):420-430

248. Hoefsmit EP, van Royen PT, Rao D, Stunnenberg JA, Dimitriadis P, Liefstink C, Morris B, Rozeman EA, Reijers ILM, Lacroix R, Shehwana H, Ligtenberg MA, Beijersbergen RL, Peeper DS, **Blank CU**. *Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells. Cancer Immunol Res. 2023 Apr 3;11(4):450-465*
249. Hoefsmit EP, Völlmy F, Rozeman EA, Reijers ILM, Versluis JM, Hoekman L, van Akkooi ACJ, Long GV, Schadendorf D, Dummer R, Altelaar M, **Blank CU**. *Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence. Cancer Res Commun. 2023 Apr 20;3(4):672-683*
250. Voorwerk L, Isaeva OI, Horlings HM, Balduzzi S, Chelushkin M, Bakker NAM, Champanhet E, Garner H, Sikorska K, Loo CE, Kemper I, Mandjes IAM, de Maaker M, van Geel JJJ, Boers J, de Boer M, Salgado R, van Dongen MGJ, Sonke GS, de Visser KE, Schumacher TN, **Blank CU**, Wessels LFA, Jager A, Tjan-Heijnen VCG, Schröder CP, Linn SC, Kok M. *PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial. Nat Cancer. 2023 Apr;4(4):535-549*
251. Reijers ILM, Rao D, Versluis JM, Menzies AM, Dimitriadis P, Wouters MW, Spillane AJ, Klop WMC, Broeks A, Bosch LJW, Lopez-Yurda M, van Houdt WJ, Rawson RV, Griepink-Ongering LG, Gonzalez M, Cornelissen S, Bouwman J, Sanders J, Plasmeijer E, Elshot YS, Scolyer RA, van de Wiel BA, Peeper DS, van Akkooi ACJ, Long GV, **Blank CU**. *IFN- γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma. J Exp Med. 2023 May 1;220(5):e20221952*
252. Zijlker LP, van der Burg SJC, **Blank CU**, Zuur CL, Klop WMC, Wouters MWMJ, van Houdt WJ, van Akkooi ACJ. *Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery. Eur J Cancer. 2023 May;185:131-138*
253. van Not OJ, Wind TT, Ismail RK, Bhattacharya A, Jalving M, **Blank CU**, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Haanen JB, Kapiteijn E, Bloem M, Piersma D, van Rijn RS, Stevense-den Boer M, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Blokx WAM, Suijkerbuijk KPM, Fehrmann RSN, Hospers GAP. *A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors. Cancers (Basel). 2023 May 26;15(11):2922*
254. Rao D, Stunnenberg JA, Lacroix R, Dimitriadis P, Kaplon J, Verburg F, van van Royen PT, Hoefsmit EP, Renner K, **Blank CU**, Peeper DS. *Acidity-mediated induction of FoxP3⁺ regulatory T cells. Eur J Immunol. 2023 Jun;53(6)*
255. Van Not OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Boers-Sonderen MJ, van Eijs MJM, de Groot JB, Hospers GAP, Kapiteijn E, de Meza M, Piersma D, Stevense-den Boer M, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Suijkerbuijk KPM, Blokx WAM. *Response to checkpoint*

inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies. Eur J Cancer. 2023 Jun;186:27-37

256. Groenland SL, Janssen JM, Nijenhuis CM, de Vries N, Rosing H, Wilgenhof S, van Thienen JV, Haanen JBAG, **Blank CU**, Beijnen JH, Huitema ADR, Steeghs N. *Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients. Cancer Chemother Pharmacol. 2023 Jun;91(6):447-456*
257. van Duin IAJ, Elias SG, van den Eertwegh AJM, de Groot JWB, Blokk WAM, van Diest PJ, Leiner T, Verhoeff JJC, Verheijden RJ, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Haanen JBAG, Hospers GAP, Kamphuis AM, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Stevense-den Boer MAM, Boers-Sonderen MJ, Kapiteijn E, Suijkerbuijk KPM. *Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma. Int J Cancer. 2023 Jun 15;152(12):2493-2502*
258. van Zeijl MCT, van Breeschoten J, de Wreede LC, Wouters MWJM, Hilarius DL, **Blank CU**, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MA, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Suijkerbuijk KPM, Haanen JBAG, van den Eertwegh AJM. *Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands. J Immunother. 2023 Jun 1;46(5):197-204*
259. Lucas MW, Versluis JM, Rozeman EA, **Blank CU**. *Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. Nat Rev Clin Oncol. 2023 Jun;20(6):408-422*
260. de Meza MM, Blokk WAM, Bonenkamp HJ, **Blank CU**, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB, Haanen JB, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Stevense-Den Boer MA, van der Veldt AAM, Vreugdenhil G, van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. *Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials. Int J Cancer. 2023 Jul 15;153(2):389-398*
261. Rozeman EA, Versluis JM, Sikorska K, Hoefsmit EP, Dimitriadis P, Rao D, Lacroix R, Griepink-Ongering LG, Lopez-Yurda M, Heeres BC, van de Wiel BA, Flohil C, Sari A, Heijmink SWTPJ, van den Broek D, Broeks A, de Groot JWB, Vollebergh MA, Wilgenhof S, van Thienen JV, Haanen JBAG, **Blank CU**. *IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation. J Immunother Cancer. 2023 Jul;11(7)*
262. Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suci S, **Blank CU**, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khatkhat A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. *Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of*

- pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer. 2023 Aug;189:112900*
263. Borgers JSW, Burgers FH, Schina A, Van Not OJ, van den Eertwegh AJM, **Blank CU**, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Boer AMS, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Wouters MWJM, Suijkerbuijk KPM, van Thienen JV, Haanen JBAG. *Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort. Pigment Cell Melanoma Res. 2023 Aug 8*
264. Egeler MD, van de Poll-Franse LV, Tissier R, Rogiers A, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, de Groot JWB, Aarts MJB, Kapiteijn E, Piersma D, Vreugdenhil G, van der Veldt AA, Suijkerbuijk KPM, Neyns B, Janssen KJ, **Blank CU**, Retel VP, Boekhout AH. *Health-state utilities in long-term advanced melanoma survivors comparable with the general population. Qual Life Res. 2023 Sep;32(9):2517-2525*
265. Hoeijmakers LL, Reijers ILM, **Blank CU**. *Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma. Cancer Discov. 2023 Sep 5:OF1-OF20*
266. Miao B, Hu Z, Mezzadra R, Hoeijmakers L, Fauster A, Du S, Yang Z, Sator-Schmitt M, Engel H, Li X, Broderick C, Jin G, Gomez-Eerland R, Rozeman L, Lei X, Matsuo H, Yang C, Hofland I, Peters D, Broeks A, Laport E, Fitz A, Zhao X, Mahmoud MAA, Ma X, Sander S, Liu HK, Cui G, Gan Y, Wu W, Xiao Y, Heck AJR, Guan W, Lowe SW, Horlings HM, Wang C, Brummelkamp TR, **Blank CU**, Schumacher TNM, Sun C. *CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1. Cancer Cell. 2023 Oct 9;41(10):1817-1828*
267. Schmitt C, Hoefsmit EP, Fangmeier T, Kramer N, Kabakci C, Vera González J, Versluis JM, Compter A, Harrer T, Mijočević H, Schubert S, Hundsberger T, Menzies AM, Scolyer RA, Long GV, French LE, **Blank CU**, Heinzerling LM. *Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections. Cancer Immunol Immunother. 2023 Nov;72(11)*
268. Hepner A, Versluis JM, Wallace R, Allayous C, Brown LJ, Trojaniello C, Gerard CL, Jansen YJ, Bhave P, Neyns B, Haydon A, Michielin O, Mangana J, Klein O, Shoushtari AN, Warner AB, Ascierto PA, McQuade JL, Carlino MS, Zimmer L, Lebbe C, Johnson DB, Sandhu S, Atkinson V, **Blank CU**, Lo SN, Long GV, Menzies AM. *The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. Eur J Cancer. 2023 Nov 20;196:113441*
269. Fraterman I, Reijers ILM, Dimitriadis P, Broeks A, Gonzalez M, Menzies AMM, Lopez-Yurda M, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Hospers GAP, Long GV, **Blank CU**, van de Poll-Franse LV. *Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma. Nat Med. 2023 Nov 13*

270. Hepner A, Versluis JM, Wallace R, Allayous C, Brown LJ, Trojaniello C, Gerard CL, Jansen YJ, Bhave P, Neyns B, Haydon A, Michielin O, Mangana J, Klein O, Shoushtari AN, Warner AB, Ascierto PA, McQuade JL, Carlino MS, Zimmer L, Lebbe C, Johnson DB, Sandhu S, Atkinson V, **Blank CU**, Lo SN, Long GV, Menzies AM. *The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. Eur J Cancer. 2024 Jan;196:113441. doi: 10.1016/j.ejca.2023.113441.*
271. Tong TML, Bastiaannet E, Speetjens FM, **Blank CU**, Luyten GPM, Jager MJ, Marinkovic M, Vu THK, Rasch CRN, Creutzberg CL, Beenakker JM, Hartgrink HH, Bosch JJJ, Kiliç E, Naus NC, Yavuziyigitoglu S, van Rij CM, Burgmans MC, Kapiteijn EHW. *Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period. Cancers (Basel). 2023 Nov 15;15(22):5419. doi: 10.3390/cancers15225419.*
272. Van Not OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Boers-Sonderen MJ, de Groot JWJB, Hospers GAP, Kapiteijn E, Bloem M, Piersma D, Stevense-den Boer M, Verheijden RJ, van der Veldt AAM, Wouters MWJM, Blokk WAM, Suijkerbuijk KPM. *BRAF/MEK inhibitor rechallenge in advanced melanoma patients. Cancer. 2024 May 1;130(9):1673-1683. doi: 10.1002/cncr.35178.*
273. Versluis JM, Hoefsmit EP, Shehwana H, Dimitriadis P, Sanders J, Broeks A, **Blank CU**. *Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma. Cancer Immunol Immunother. 2024 Jan 27;73(2):28. doi: 10.1007/s00262-023-03581-6.*
274. van Duin IAJ, Verheijden RJ, van Diest PJ, Blokk WAM, El-Sharouni MA, Verhoeff JJC, Leiner T, van den Eertwegh AJM, de Groot JWB, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Stevense-den Boer MAM, Boers-Sonderen MJ, Kapiteijn E, Suijkerbuijk KPM, Elias SG. *A prediction model for response to immune checkpoint inhibition in advanced melanoma. Int J Cancer. 2024 May 15;154(10):1760-1771. doi: 10.1002/ijc.34853. Epub 2024 Jan 31.*
275. van Not OJ, van den Eertwegh AJM, Haanen JB, **Blank CU**, Aarts MJB, van Breeschoten J, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Ismail RK, Kapiteijn E, Bloem M, De Meza MM, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Blokk WAM, Wouters MWJM, Suijkerbuijk KPM. *Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021. EClinicalMedicine. 2024 Feb 12;69:102485. doi: 10.1016/j.eclinm.2024.102485. eCollection 2024 Mar.*
276. Kennedy OJ, Glassee N, Kicinski M, **Blank CU**, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Giacomo AMD, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Gandini S, Buhner E, Suci S, Robert C, Eggermont AMM, Mandala M, Lorigan P, Valpione S. *Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of*

- pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer. 2024 Apr;201:113585. doi: 10.1016/j.ejca.2024.113585. Epub 2024 Feb 1.*
277. Versluis JM, Blankenstein SA, Dimitriadis P, Wilmott JS, Elens R, Blokk WAM, van Houdt W, Menzies AM, Schrage YM, Wouters MWJM, Sanders J, Broeks A, Scolyer RA, Suijkerbuijk KPM, Long GV, Akkooi ACJV, **Blank CU**. *Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma. J Immunother Cancer. 2024 Apr 27;12(4):e008125. doi: 10.1136/jitc-2023-008125.*
278. Embaby A, Huijberts SCFA, Wang L, Leite de Oliveira R, Rosing H, Nuijen B, Sanders J, Hofland I, van Steenis C, Kluin RJC, Lieftink C, Smith CG, **Blank CU**, van Thienen JV, Haanen JBAG, Steeghs N, Opdam FL, Beijnen JH, Huitema ADR, Bernardis R, Schellens JHM, Wilgenhof S. *A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma. Clin Cancer Res. 2024 Aug 1;30(15):3157-3166. doi: 10.1158/1078-0432.CCR-23-3171.*
279. Janssen JC, van Dijk B, de Joode K, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Jalving M, de Jonge MJA, Joosse A, Kapiteijn E, Kamphuis-Huismans AM, Naipal KAT, Piersma D, Rikhof B, Westgeest HM, Vreugdenhil G, Oomen-de Hoop E, Mulder EEAP, van der Veldt AAM. *Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab-study protocol. BMC Cancer. 2024 May 23;24(1):632. doi: 10.1186/s12885-024-12336-0.*
280. **Blank CU**, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, Hoeijmakers LL, Saw RPM, Lijnsvelt JM, Maher NG, Pulleman SM, Gonzalez M, Torres Acosta A, van Houdt WJ, Lo SN, Kuijpers AMJ, Spillane A, Klop WMC, Pennington TE, Zuur CL, Shannon KF, Seinstra BA, Rawson RV, Haanen JBAG, Ch'ng S, Naipal KAT, Stretch J, van Thienen JV, Rtshiladze MA, Wilgenhof S, Kapoor R, Meerveld-Eggink A, Griepink-Ongering LG, van Akkooi ACJ, Reijers ILM, Gyorki DE, Grünhagen DJ, Speetjens FM, Vlieg SB, Placzke J, Spain L, Stassen RC, Amini-Adle M, Lebbé C, Faries MB, Robert C, Ascierto PA, van Rijn R, van den Berkmortel FWPJ, Piersma D, van der Westhuizen A, Vreugdenhil G, Aarts MJB, Stevense-den Boer MAM, Atkinson V, Khattak M, Andrews MC, van den Eertwegh AJM, Boers-Sonderen MJ, Hospers GAP, Carlino MS, de Groot JB, Kapiteijn E, Suijkerbuijk KPM, Rutkowski P, Sandhu S, van der Veldt AAM, Long GV. *Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med. 2024 Nov 7;391(18):1696-1708. doi: 10.1056/NEJMoa2402604. Epub 2024 Jun 2.*
281. Verheijden RJ, Burgers FH, Janssen JC, Putker AE, Veenstra SPGR, Hospers GAP, Aarts MJB, Hehenkamp KW, Doornebosch VLE, Verhaert M, van den Berkmortel FWPJ, Chatzidionysiou K, Llobell A, Barros M, Maria ATJ, Takeji A, García Morillo JS, Lidar M, van Eijs MJM, **Blank CU**, Aspeslagh S, Piersma D, Kapiteijn E, Labots M, Boers-Sonderen MJ, van der Veldt AAM, Haanen JBAG, May AM, Suijkerbuijk KPM. *Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma. Eur J Cancer. 2024 Aug;207:114172. doi: 10.1016/j.ejca.2024.114172. Epub 2024 Jun 15.*

282. Bloem M, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Blokk WAM, Boers-Sonderen MJ, Bonenkamp JJ, de Groot JB, Haanen JB, Hospers GAP, Kapiteijn EW, de Meza MM, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. *Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study. Int J Cancer. 2024 Oct 15;155(8):1455-1465. doi: 10.1002/ijc.35060. Epub 2024 Jun 24.*
283. Rauwerdink DJW, Not OV, de Meza M, Doorn RV, Hage JV, Eertwegh AJMVD, Haanen JB, Aarts MJB, Berkmortel FWPJVD, Blank CU, Boers-Sonderen MJ, Groot JWB, Hospers GAP, Piersma D, van Rijn RS, Stevense-den Boer AM, Veldt AAMV, Vreugdenhil G, Wouters MWJM, Suijkerbuijk KPM, Kapiteijn E. *Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients. Cancers (Basel). 2024 Jul 26;16(15):2656. doi: 10.3390/cancers16152656.*
284. van Not OJ, van den Eertwegh AJM, Jalving H, Bloem M, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Boers-Sonderen MJ, de Groot JWB, Hospers GAP, Kapiteijn E, Leeneman B, D P, Stevense-den Boer M, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Blokk WAM, Suijkerbuijk KPM. *Long-Term Survival in Patients With Advanced Melanoma. JAMA Netw Open. 2024 Aug 1;7(8):e2426641. doi: 10.1001/jamanetworkopen.2024.26641.*
285. Bühner E, Kicinski M, Mandala M, Pe M, Long GV, Atkinson V, **Blank CU**, Haydon A, Dalle S, Khattak A, Carlino MS, Meshcheryakov A, Sandhu S, Puig S, Schadendorf D, Jamal R, Rutkowski P, van den Eertwegh AJM, Coens C, Grebennik D, Krepler C, Robert C, Eggermont AMM. *Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2024 Sep;25(9):1202-1212. doi: 10.1016/S1470-2045(24)00338-3. Epub 2024 Aug 12.*
286. Yeghaian M, Bodalal Z, Tareco Bucho TM, Kurilova I, **Blank CU**, Smit EF, van der Heijden MS, Nguyen-Kim TDL, van den Broek D, Beets-Tan RGH, Trebeschi S. *Integrated noninvasive diagnostics for prediction of survival in immunotherapy. Immuno-oncol Technol. 2024 Jul 9;24:100723. doi: 10.1016/j.iotech.2024.100723. eCollection 2024 Dec.*
287. Nederlof I, Isaeva OI, de Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL, Garner H, Boeckx B, Traets JJH, Mandjes IAM, de Maaker M, van Brussel T, Chelushkin M, Champanhet E, Lopez-Yurda M, van de Vijver K, van den Berg JG, Hofland I, Klioueva N, Mann RM, Loo CE, van Duijnhoven FH, Skinner V, Luyckx S, Kerver E, Kalashnikova E, van Dongen MGJ, Sonke GS, Linn SC, **Blank CU**, de Visser KE, Salgado R, Wessels LFA, Drukker CA, Schumacher TN, Horlings HM, Lambrechts D, Kok M. *Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial. Nat Med. 2024 Nov;30(11):3223-3235. doi: 10.1038/s41591-024-03249-3. Epub 2024 Sep 16.*
288. Eggermont AM, Kicinski M, **Blank CU**, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh

- AJ, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Lorigan P, Grebennik D, Kreplere C, Marreaud S, Suciú S, Robert C. *Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial. Eur J Cancer. 2024 Nov;211:114327. doi: 10.1016/j.ejca.2024.114327. Epub 2024 Sep 12.*
289. Woodford R, McKeown J, Hoeijmakers LL, Mangana J, Dimitriou F, Allayous C, Zaman F, Aya F, Marsiglio J, Goodman R, Rayson V, Placzke J, Kessels J, Ramalyte E, Haque W, Wilson I, Trojaniello C, Benannoune N, Roberts-Thomson R, Robert C, **Blank CU**, Dummer R, Lebbe C, Haydon A, Arance A, Hu-Lieskovan S, Johnson DB, McArthur GA, Rutkowski P, Neyns B, Sullivan RJ, Weber J, Carlino MS, Ascierto PA, Lo S, Long GV, Menzies AM. *Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy. Eur J Cancer. 2024 Nov;212:115055. doi: 10.1016/j.ejca.2024.115055. Epub 2024 Sep 29.*
290. Özkan A, Kapiteijn E, van den Bos F, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Bloem M, Blokx WAM, Boers-Sonderen MJ, Bonenkamp JJ, van den Eertwegh AJM, de Groot JWB, Haanen JB, Holtslag CE, Hospers GAP, Piersma D, van Rijn RS, Stevensen-den Boer AM, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Portielje JEA, de Glas NA. *Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry. Eur J Cancer. 2024 Nov;212:115056. doi: 10.1016/j.ejca.2024.115056.*
291. Macandog ADG, Catozzi C, Capone M, Nabinejad A, Nanaware PP, Liu S, Vinjamuri S, Stunnenberg JA, Galiè S, Jodice MG, Montani F, Armanini F, Cassano E, Madonna G, Mallardo D, Mazzi B, Pece S, Tagliamonte M, Vanella V, Barberis M, Ferrucci PF, **Blank CU**, Bouvier M, Andrews MC, Xu X, Santambrogio L, Segata N, Buonaguro L, Cocorocchio E, Ascierto PA, Manzo T, Nezi L. *Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients. Cell Host Microbe. 2024 Nov 13;32(11):2004-2018.e9. doi: 10.1016/j.chom.2024.10.006.*
292. Janssen JC, van Dijk B, Hoeijmakers LL, Grünhagen DJ, Bramer WM, Verhoef C, de Gruijl TD, **Blank CU**, van der Veldt AAM. *Local administration of immunotherapy for patients with skin cancer: A systematic review. Cancer Treat Rev. 2024 Dec;131:102848. doi: 10.1016/j.ctrv.2024.102848.*
293. Vos JL, Traets JJ, Qiao X, Seignette IM, Peters D, Wouters MW, Hooijberg E, Broeks A, van der Wal JE, Karakullukcu MB, Klop WMC, Navran A, van Beurden M, Brouwer OR, Morris LG, van Poelgeest MI, Kapiteijn E, Haanen JB, **Blank CU**, Zuur CL. *Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma. JCI Insight. 2024 Nov 8;9(21):e179982. doi: 10.1172/jci.insight.179982.PMID: 39513365*
294. Reijers ILM, Menzies AM, Lopez-Yurda M, Versluis JM, Rozeman EA, Saw RPM, van Houdt WJ, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Eriksson H, Hospers GAP, Klop WMC, Torres Acosta A, Grijpink-Ongering L, Gonzalez M, van der Wal A, Al-Mamgani A, Spillane AJ, Scolyer RA, van de Wiel BA, van Akkooi ACJ, Long GV, **Blank CU**. *Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo. Eur J Cancer. 2024 Nov 19;214:115141. doi: 10.1016/j.ejca.2024.115141.*

295. Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, **Blank CU**, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV. *Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell.* 2025 Feb 6;S1535-6108(25)00029-7. doi: 10.1016/j.ccell.2025.01.011. Online ahead of print.
296. Dummer R, Sandhu S, Miller WH Jr, Butler MO, Taylor MH, Heinzerling L, **Blank CU**, Muñoz-Couselo E, Burris HA 3rd, Postow MA, Chmielowski B, Middleton MR, Berking C, Hassel JC, Gesierich AH, Mauch C, Kleha JF, Polli A, Harney AS, di Pietro A, Ascierto PA. *Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma. Clin Cancer Res.* 2025 Jun 3;31(11):2097-2107
297. Zhou L, Barros E Silva MJ, Hsiao E, Eroglu Z, Sandhu S, Samoylenko I, Lo SN, Carlino MS, Au-Yeung G, Gonzalez M, Spillane AJ, Pennington TE, Shannon KF, Kapoor R, Burton EM, Tawbi HA, Amaria RN, **Blank CU**, Duprat JP, Brito de Paula R, Gyorki DE, Saw RPM, Ch'Ng S, Rawson RV, Scolyer RA, Pires da Silva I, Akkooi ACJV, Long GV, Menzies AM. *FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. J Immunother Cancer.* 2025 Mar 25;13(3):e011483.
298. Bloem M, de Meza MM, van den Eertwegh AJM, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Blokkx WAM, Boers-Sonderen MJ, Bonenkamp JJ, Boreel CDM, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, van Not OJ, Piersma D, Rikhof B, Stevensen-den Boer AM, van der Veldt AAM, Vreugdenhil G, Suijkerbuijk KPM, Wouters MWJM. *Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis. Br J Cancer.* 2025 Jun;132(12):1124-1130
299. Hoeijmakers LL, Rozeman EA, Lopez-Yurda M, Griepink-Ongering LG, Heeres BC, van de Wiel BA, Flohil C, Sari A, Heijmink SWTPJ, van den Broek D, Broeks A, de Groot JWB, Vollebergh MA, Wilgenhof S, van Thienen JV, Haanen JBAG, **Blank CU**. *Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial. Eur J Cancer.* 2025 Jun 3;222:115431
300. van Dijk EJ, Nienhuis HH, van den Eertwegh AJM, Boers-Sonderen MJ, Bloem M, Kamphuis AM, Ros MM, Bos C, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Blokkx WAM, de Groot JWB, Hospers GAP, Piersma D, van Rijn RS, Stevensen-den Boer AM, Vreugdenhil G, Wouters MWJM, Kapiteijn E, Haanen JB, van der Veldt AAM, Suijkerbuijk KPM. *Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy. Br J Cancer.* 2025 Jul;133(1):66-75
301. Bloem M, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, **Blank CU**, Blokkx WAM, Boers-Sonderen MJ, Boreel CDM, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, van Not OJ, Piersma D, Rikhof B, Stevensen-den Boer AM, van der Veldt

- AAM, Vreugdenhil G, Wouters MWJM, van den Eertwegh AJM. *Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry*. *Eur J Cancer*. 2025 Jun 18;223:115514
302. Lijnsvelt JM, Lievens Z, Albers EAC, Lopez-Yurda M, van de Poll-Franse LV, **Blank CU**. *Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients*. *J Cancer Surviv*. 2025 May 26. doi: 10.1007/s11764-025-01825-1. Online ahead of print
303. Nelson A, Krabbe E, Björkström K, Huibers A, Jovanovic B, **Blank CU**, Ullenhag GJ, Helgadottir H, Ny L, Olofsson Bagge R. *Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma - A Swedish retrospective real-world study (NEO-MEL)*. *Eur J Cancer*. 2025 Jun 25;224:115485
304. Awada G, Cascone T, van der Heijden MS, **Blank CU**, Kok M, Chalabi M. *The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types*. *Nat Cancer*. 2025 Jun;6(6):967-987
305. Wijnen SCMA, Dimitriadis P, Reijers ILM, Menzies AM, Long GV, Wessels LFA, **Blank CU**. *Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures*. *Cancer Immunol Immunother*. 2025 Jun 25;74(8):253
306. Egeler MD, Klobuch S, Tak WS, Rohaan MW, Borch TH, Noringriis IM, Tissier R, Lucas MW, van Houdt W, van Akkooi ACJ, Jedema I, Donia M, **Blank CU**, Svane IM, Haanen JBAG, van de Poll-Franse LV. *The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma*. *Eur J Cancer*. 2025 Sep 9;227:115640
307. Menzer C, Dugas-Breit S, Dugas M, **Blank CU**, Groen EJ, Reijers I, Schlaak M, Eckardt J, Suijkerbuijk KPM, Zimmer L, Johnson DB, Franklin C, Meiss F, Schilling B, Meier F, Gutzmer R, Thoms KM, Haalck T, Müller M, Kopp-Schneider A, Carlino MS, Long GV, Menzies AM, van der Veldt AAM, de Groot JWB, Eigentler T, Stevense-den Boer M, Pföhler C, Herbschleb K, Hassel JC. *Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database*. *Eur J Cancer*. 2025 Oct 1;228:115703
308. Albers EAC, Luijendijk MJ, Egeler M, Fraterman I, Lucas MW, de Ligt KM, Schagen SB, **Blank CU**, van de Poll-Franse LV. *Cross-sectional study of long-term Health-Related Quality of Life in stage III melanoma patients receiving neo-adjuvant versus adjuvant immune checkpoint inhibitors*. *Eur J Cancer*. 2025 Oct 16;229:115710
309. Fallarino F, **Blank CU**. *Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape*. *Nat Rev Immunol*. 2025 Sep 22. doi: 10.1038/s41577-025-01222-w. Online ahead of print
310. Versluis JM, Shehwana H, Elens R, Menzies AM, Reijers ILM, Dimitriadis P, Maher NG, van der Veldt AMM, Kapiteijn E, Broeks A, Scolyer RA, van de Wiel BA, van Akkooi ACJ, Schumacher TN, Long GV, **Blank CU**. *Clinical, pathological and molecular characteristics of patients*

with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma. Commun Med (Lond). 2025 Sep 30;5(1):407